
==== Front
Cell Commun Signal
Cell Commun Signal
Cell Communication and Signaling : CCS
1478-811X
BioMed Central London

1811
10.1186/s12964-024-01811-7
Review
Targeting the EphA2 pathway: could it be the way for bone sarcomas?
Giordano Giorgia 12
Tucciarello Cristina 13
Merlini Alessandra 2
Cutrupi Santina 3
Pignochino Ymera ymera.pignochino@ircc.it

13
1 https://ror.org/04wadq306 grid.419555.9 0000 0004 1759 7675 Sarcoma Unit, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, TO Italy
2 https://ror.org/048tbm396 grid.7605.4 0000 0001 2336 6580 Department of Oncology, University of Turin, 10043 Orbassano, TO Italy
3 https://ror.org/048tbm396 grid.7605.4 0000 0001 2336 6580 Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, TO Italy
9 9 2024
9 9 2024
2024
22 4339 4 2024
30 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Bone sarcomas are malignant tumors of mesenchymal origin. Complete surgical resection is the cornerstone of multidisciplinary treatment. However, advanced, unresectable forms remain incurable. A crucial step towards addressing this challenge involves comprehending the molecular mechanisms underpinning tumor progression and metastasis, laying the groundwork for innovative precision medicine-based interventions. We previously showed that tyrosine kinase receptor Ephrin Type-A Receptor 2 (EphA2) is overexpressed in bone sarcomas. EphA2 is a key oncofetal protein implicated in metastasis, self-renewal, and chemoresistance. Molecular, genetic, biochemical, and pharmacological approaches have been developed to target EphA2 and its signaling pathway aiming to interfere with its tumor-promoting effects or as a carrier for drug delivery. This review synthesizes the main functions of EphA2 and their relevance in bone sarcomas, providing strategies devised to leverage this receptor for diagnostic and therapeutic purposes, with a focus on its applicability in the three most common bone sarcoma histotypes: osteosarcoma, chondrosarcoma, and Ewing sarcoma.

Keywords

EphA2
Bone sarcomas
Targeted therapy
Immunotherapy
Drug delivery
Ministero della SaluteGR-2016-02362726 Department of Clinical and Biological SciencesRILO 2021_01 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Bone sarcomas belong to a rare and heterogeneous group of malignant mesenchymal primary tumors originating from the osseous tissue, representing less than 1% of all malignancies [1]. Osteosarcoma (OS) and Ewing sarcoma (ES) occur mainly in adolescents and young adults, while chondrosarcoma (CS) has a peak incidence in the seventh decade of age [2]. Surgical excision of the tumor combined with radiotherapy and chemotherapy can achieve good results as first-line treatment; however, 40% of patients affected by bone sarcomas still die of the disease due to poor histological response to therapy, onset of multiple metastases, and relapses [3]. Several targeted therapies and immunotherapies against advanced unresectable bone sarcomas have been investigated in preclinical and clinical studies. Still, among innovative agents, only mifamurtide has entered the clinical management of OS until now [4, 5]. Identifying novel molecular targets will be instrumental in overcoming the current impasse in treating relapsing disease. Receptor tyrosine kinases (RTKs) have been extensively studied as therapeutic targets in bone sarcoma, being implicated in several steps of their onset and progression [6–13]. Among them, the erythropoietin-producing hepatocellular (Eph) tyrosine kinases receptor family member 2 (EphA2) is a driver oncofetal protein implicated in self-renewal, chemoresistance, and metastasis [14–16] so that its targeting is now under preclinical and clinical investigation [17–21]. We previously showed that bone sarcoma patient-derived models overexpressed EphA2 and are sensitive to its inhibition [7, 13]. In the present work, we combined a thorough overview of the literature to pursue the current knowledge of EphA2 functions in different tumors, focusing on bone sarcomas, and the main strategies developed so far for its specific targeting, exploring its potential applicability in these settings.

Eph receptors signaling and ephrins

Eph receptors belong to a large subfamily of RTKs expressed in various cell types in developing and mature tissues [22, 23]. They have a highly conserved overall structure and are subdivided into two classes: EphA and EphB, based on their extracellular domain sequence homology and ligand binding specificity. In humans, nine EphA (A1-8, A10) and five EphB (B1-4, B6) receptors were identified with eight related ligands (Ephrin-A1-5 and Ephrin-B1-3) [24, 25]. The EphA receptor members bind preferentially to Ephrin-A ligands, while the EphB receptors bind to Ephrin-Bs, with some exceptions of cross-class binding such as EphA4, which interacts with Ephrin-B2 and B3, while EphB2 with Ephrin-A5 [26].

Eph receptors are single transmembrane proteins constituted by an extracellular side, which exerts ligand-binding activity and an intracellular side with intrinsic enzymatic properties [26]. Starting from the N-terminal, the extracellular side of Eph receptors is composed of a ligand-binding domain (LBD) followed by a Cys-rich domain composed of the Sushi and the Epidermal Growth Factor (EGF)-like domains, and two fibronectin (FN) domains. The intracellular part of the Eph receptor is composed of the transmembrane (TM) region, the tyrosine kinase (TK) domain, the Sterile Alpha Motif (SAM), and the common structural PDZ domain (Fig. 1). The Eph ligands, Ephrins, are anchored to the cell membrane of interacting cells and share a conserved extracellular N-terminal receptor-binding domain (RBD) [25]. Class A is linked to the membrane through a glycosylphosphatidylinositol (GPI) linkage, whereas class B has a TM domain and an intracellular tail ending with a PDZ domain [24]. The interaction between Eph receptors and their ligands leads to the phosphorylation of various tyrosine (Tyr) residues between the TM and SAM domains. These post-translational modifications are crucial for the occurrence of the biological responses triggered by Eph signaling (Fig. 1).

Fig. 1 Schematic representation of the structural and functional domains of Eph receptor and its ligands. Eph receptors are single transmembrane proteins constituted by an extracellular and an intracellular side. The extracellular side is composed of a ligand-binding domain (LBD), a Cys-rich domain made of the Sushi and the Epidermal Growth Factor (EGF)-like domains, and two fibronectin (FN1 and FN2) domains. The intracellular side is composed of the transmembrane (TM) region, the tyrosine kinase (TK) domain, the Sterile Alpha Motif (SAM), and the PDZ domain. Ephrin ligands are constituted by a receptor-binding domain (RBD). Class A Ephrins are linked to the membrane through the GPI linkage, while class B Ephrins have a TM domain and an intracellular tail ending with a PDZ domain. Ephrins can be released from the cell surface by proteolytic cleavage done by proteases such as MMPs and ADAMs and can activate Eph receptors in a paracrine manner. (Created with BioRender.com)

Physiologically, the Eph-Ephrin signaling pathway intervenes in multiple biological events such as axon guidance, tissue patterning, and blood vessel development in embryonic cells [27, 28]. It is strictly dependent on cell type and microenvironment and works bi-directionally. Namely, it can affect both the receptor-expressing and the ligand-expressing cells [4, 22, 24]. Indeed, when the Eph receptor interacts with its ligand Ephrin on the adjacent cell, it initiates bidirectional signaling, which can be categorized as “forward” or “reverse” depending on the direction of signal flow. The classical forward signal (Ephrin: Eph) is often cell repulsive, dependent on Eph kinase activity and it propagates in the Eph receptor-expressing cell; conversely, the reverse signal (Eph: Ephrin) is dependent on Fyn, a kinase belonging to the Src family, and it propagates in the Ephrin-expressing cell [27, 28] (Fig. 2A). Furthermore, as both Eph receptors and Ephrins can function concurrently as receptors and ligands when present on opposing cells, we can distinguish between simultaneous parallel or antiparallel signaling based on the direction of signal propagation. Signaling is deemed “parallel” if the Eph-Ephrin complex transmits the signal in the same direction and “antiparallel” if it transmits the signal in opposite directions [22, 29] (Fig. 2B).

Fig. 2 Schematic representation of the directional signaling evoked by Eph-Ephrin binding between adjacent interacting cells. (A) Eph receptor interacts with its ligand Ephrin on the adjacent cell, initiating a bidirectional signal, “forward” or “reverse”, based on the direction of signal flow. (B) The signal could also be “parallel” or “antiparallel”, if the Eph-Ephrin complex transmits the signal in the same or opposite directions, respectively. (Created with BioRender.com)

Proteolytic cleavage serves as a feedback mechanism of this signaling process. However, the extracellular portions of shed Eph and Ephrin can interact with distant cells autonomously, independent of cell-cell contact, resulting in paracrine effects [30, 31]. For instance, they may act as monomeric inhibitors of bidirectional signaling [32]. Alternatively, cleaved ligands activate Eph receptors in an endocrine way. Soluble A-type Ephrin oligomers produced by the cleavage of GPI-anchored Ephrin-A1 on the plasma membrane by matrix metalloproteases (MMPs) or proteases of the A disintegrin and metalloproteinase (ADAM) family have the potential to activate EphA receptors, disrupting cell-cell contacts and increasing endothelial permeability which facilitates tumor metastasis to lungs [33, 34]. Soluble B-type Ephrins are involved in pathological conditions such as fibrosis and cancers [35] (Fig. 1).

EphA2 is an oncofetal protein

Among Eph receptors, EphA2 is the most widely overexpressed in different tumor types [29]. EphA2 is a 130 kDa transmembrane glycoprotein of 976 amino acids encoded by the gene EPHA2 in the human genome on chromosome 1p36 [36]. EphA2 could be described as a fetal oncoprotein since it physiologically plays key roles in several biological processes during development, including embryonic lens and inner ear formation, mammary epithelial branching morphogenesis, kidney development, and bone homeostasis, and it is aberrantly reactivated in several solid tumors [37–40].

EphA2 interacts with all the Ephrin-A family ligands with preferential binding to Ephrin-A1 (EFNA1), a Tumor Necrosis Factor (TNF)-α–inducible gene product [41]. During embryogenesis, its physiological functions following cell-cell contact rely on the binding with EFNA1 on the neighboring cells generating both reverse and forward signaling [27, 42]. During oncogenesis, EphA2 is overexpressed and signal transduction leads to modifications in cytoskeleton dynamics, cell adhesion, migration, metastasis, proliferation, and angiogenesis [43].

During normal development, the ligand-dependent EphA2 activation suppresses the Extracellular signal-regulated Kinases (ERKs), the Akt, and Focal Adhesion Kinase (FAK) signaling pathways inhibiting cell proliferation, resistance to apoptosis, and migration [44] (Fig. 3A). However, in cancers, EphA2 is involved in a non-canonical activation through different mechanisms: (i) the dimerization with other RTKs such as the Epidermal Growth Factor Receptor (EGFR); the Human Epidermal Growth Factor Receptor-2 (HER2) [45, 46]; some members of the Fibroblast Growth Factor Receptors (FGFRs); and Vascular Endothelial Growth Factor Receptors, (VEGFRs), or with cell adhesion molecules (e.g. E-cadherin and integrins) [47, 48]; (ii) the direct binding with growth factors (e.g. the Platelet-Derived Growth Factor subunit A, PDGFA [49]; iii.) the direct phosphorylation of Serine-897 (P-Ser897 EphA2) located between the TK and SAM intracellular domains by intracellular oncogenic activated kinases, such as ERK Akt, and the Ribosomal S6 Kinase (RSK) [50–52]. P-Ser897 EphA2 recruits Ephexin4, a guanine nucleotide exchange factor, promoting resistance to the extracellular matrix detachment induced-cell death (anoikis), engaging the small GTPase Ras Homolog Gene Family Member G (Rho G)-Akt pathway activation (Fig. 3B) [53, 54]. EphA2 also plays a key role in integrin-mediated cell adhesion and migration through its association with FAK. In prostate cancer cells, the constitutive active EphA2/FAK complex is disassembled by the treatment with soluble EFNA1 that stimulates EphA2 Tyrosine phosphorylation and FAK dephosphorylation leading to the complex disassemble and the inhibition of cell migration [55, 56]. However, the inhibitory effect of EFNA1-induced tyrosine phosphorylation of EphA2 is reversed by the action of the Low Molecular Weight Phospho-Tyrosine Phosphatase (LMW-PTP), a protein frequently overexpressed in cancer [57]. Moreover, LMW-PTP inhibits the p190 RhoGAP, (a Rho-GTP inhibitor), destabilizing adherent junctions via a RhoA-dependent mechanism inducing cell detachment and migration [58] (Fig. 3B).

Fig. 3 Ligand-dependent and ligand-independent EphA2 signal transduction, in normal and cancer cells, respectively. (A) In normal cells, the ligand-dependent EphA2 activation induced Tyrosine (Y) and Serine (S) phosphorylation, the Epha2 clustering, suppresses the proliferation, survival, and migration signaling pathways (ERK, Akt, FAK) inhibiting cell proliferation, resistance to apoptosis, and migration, and activates c-Cbl -mediated endosomal degradation and EphA2 recycling (B) In cancers, the non-canonical ligand-independent activation of EphA2 occurs through the dimerization with other RTKs (EGFR, HER2, FGFRs, VEGFRs) or cell adhesion molecules (E-cadherin, integrins); the direct binding with other ligands such as growth factors (e.g. platelet-derived growth factor A, PDGFA); or is mediated by intracellular oncogenic kinases (Akt, PKA, PKC, ERK). This induces the phosphorylation of Ser897, promoting cell proliferation, adhesion, and migration, other than drug resistance, protection to apoptosis and anoikis. (Created with BioRender.com)

The involvement of EphA2 in several solid tumors including melanoma, bone sarcomas, glioblastoma, lung, colorectal, prostate, pancreatic, endometrial, breast, and gastric cancers is widely demonstrated [16, 59–72]. In these tumors, EphA2 was shown to correlate with tumor stages, cancer aggressiveness, metastatic potential, and poor patient survival, so that could be considered a biomarker of poor prognosis [73–77]. Moreover, some evidence has recently shown that EphA2 is implicated in tumor-microenvironment crosstalk, promotion of metastasis, and chemoresistance [17, 78–81]. EphA2 has been correlated with cancer-associated fibroblasts (CAFs) in many tumors. In gastric cancer, CAFs promote tumorigenesis through the EphA2 signaling pathway, and the treatment with the selective EphA2 inhibitor (ALW-II-41-27) or EphA2 silencing decreased the CAF-induced tumorigenesis [82]. Moreover, the EphA2-PI3K signaling pathway is involved in the CAF-induced vascular mimicry inducing gastric cancer cells to generate an endothelial-free blood delivery channel [83]. In addition, EphA2 may promote tumor-induced endothelial cell migration and angiogenesis, through its direct interaction with Caveolin-1 (CAV-1) and the consequent Akt activation and basic FGF (bFGF) production [84].

EphA2 as a potential therapeutic target in bone sarcoma

In the realm of rare tumors, bone sarcomas remain a particularly challenging category, often labeled as “drug-orphan tumors”, because of the lack of effective treatments for advanced disease. This is mainly due to their heterogeneity and rarity, which pose significant obstacles to drug discovery and the development of innovative therapy. In this context, exploring EphaA2 targeting emerges as a promising avenue [85].

Our group has provided evidence suggesting that EphA2 might be an effective molecular target in the three main bone sarcomas (OS, ES, and CS). Through a combination of in silico analyses, and in vitro experiments using bone sarcoma cell lines and patient-derived xenografts, we observed significant overexpression of EphA2 compared to healthy controls [13]. Furthermore, our studies revealed that inhibiting EphA2 directly with ALW-II-41-27 or decreasing its expression impaired bone sarcoma growth [7, 13].

EphA2 in osteosarcoma

OS is the most common primary bone tumor [3]. It mainly affects children and young adults under 25 years old. Still, a second peak of incidence usually arises at the age of 60 years with a frequency of 0.2–0.3 and 0.8/1.1 cases per 100,000 people per year in the general population and at the age of 15–19, respectively, and with a 1.4 male/female ratio [86–88]. There are 3 main types of primary osteosarcoma: intramedullary, juxtacortical, and extraskeletal osteosarcoma. The intramedullary osteosarcoma develops in the medullary cavity of a long bone is the most common (80%) and can be further divided into osteoblastic, condroblastic, fibroblastic, small-cell, and epithelioid based on main cell types. The juxtacortical osteosarcoma (10–15%) develops on the outer surface of the bones or the periosteum. The extraskeletal osteosarcoma is the rarest (< 5%) originates in soft tissues and can be induced by radiotherapy. Differences in clinical behavior and treatment choice for each subtype were exhaustively reviewed elsewhere [89]. OS is characterized by complex genetic changes and instability which result in recurrent amplifications and DNA copy number variations at different chromosomal regions [90]. Two recurrent somatic mutations implicated in the genesis of this tumor result from the progressive accumulation of genetic defects: a mutation in the Retinoblastoma Protein 1 (RB1) gene associated with retinoblastoma at 13q14 and mutations in the Tumor Protein 53 (TP53) gene associated with Li-Fraumeni syndrome at 17p13 [91]. These known tumor suppressor genes are key players in bone oncogenesis [92]. However, efficient targetingof RB1 and TP53 alterations remains elusive, and druggable gene alterations are still lacking. The standard therapeutic approach in localized OS combines surgery and polychemotherapy; in advanced disease with lung metastases, repeated lung metastasectomy can achieve a permanent cure in a subset of selected patients [93] but the overall prognosis remains dismal [94]. Fritsche-Guenther et al. showed a high overexpression of the EphA2 and its ligand in human OS samples analyzed by microarray [62]. Though EFNA1 was strongly upregulated in tumor tissues, it was also detected in fetal and normal adult human bone tissue. On the contrary, an EphA2 de novo expression has been observed in OS tumor tissue only. Furthermore, preclinical data demonstrated that this pathway activation is involved in OS progression. Therefore, the upregulation of EphA2 and its ligand in OS contributes to oncogenic signaling and might stimulate the OS metastasis process [62]. This target is also strongly expressed at the proteomic level as shown by PosthumaDeBoer et al. which observed that EphA2 was one of the most abundant and highly expressed proteins in OS cell lines and human OS samples. Furthermore, they underscored the significance of EphA2 expression in patients by establishing correlations with clinical parameters and demonstrating its association with poor overall survival [95]. Our group confirmed the pro-tumorigenic role of EphA2 in OS cells demonstrating that EphA2 silencing significantly reduced cell proliferation and migration [7]. We showed for the first time that the inhibition of EphA2 occurred after treatments with two receptor tyrosine kinase inhibitors, pazopanib and trametinib [7]. Using bioinformatic analysis, we explored the EphA2 gene expression level in 10 OS cell lines of the whole Cancer Cell Line Encyclopedia (CCLE) and its relation to patient characteristics and clinical outcomes in 88 OS samples deposited in Gene Expression Omnibus (GEO). We observed a higher expression of EphA2 in tumors with a higher Huvos grade than in the lower [13]. These findings allow us to speculate that, despite the good outcome of chemotherapy (high Huvos grade), persister cells surviving after/tolerant to chemotherapy and typically responsible for disease relapse, express higher levels of EphA2, suggesting that EphA2 could be a good target for second-line therapy, or its targeting could be combined with first-line chemotherapy to overcome drug resistance. In addition, significant upregulation of EphA2 in males compared to females was observed [13]. Considering that a worse prognosis was registered in male OS patients [96], this could be attributed to higher EphA2 expression. Overall, these data rationally support the exploration of the EphA2 targeting in OS.

EphA2 in ewing sarcoma

ES is the second most frequent malignant bone tumor among children and adolescents with a median age at diagnosis of 15 years, slightly more common in males, and an incidence of 0.3 cases per 100,000 people per year, burdened by dismal prognosis in advanced stages [97]. The survival rate is 66% at 5 years and 20% at 5 years for poor responders [88]. Genetically, they are characterized by chromosomal translocation t(11;22)(q24;q29) in which the gene encoding for the RNA-binding protein EWS (EWSR1) is fused with the ETS transcription factor FLI1 resulting in EWSR1–FLI1 fusion gene. However, although rarely, few recurrent somatic mutations were found in ES, involving Cohesin Complex Component (STAG2), TP53, and Cyclin-Dependent Kinase inhibitor 2 A (CDKN2A) or else Kinase Insert Domain Receptor (KDR), Serine/Threonine Kinase 11 (STK11), DNA mismatch repair protein Mlh1 (MLH1), Kirsten rat sarcoma virus (KRAS), and Tyrosine-Protein Phosphatase Non-Receptor Type 11 (PTPN11) [98–100]. ESs are aggressive tumors, frequently displaying micrometastases at presentation [101]. These tumors exhibit a high sensitivity to chemotherapy and nearly 2/3 of the patients can be cured through multimodal treatment strategies, based on surgery and poli-chemotherapy with vincristine, doxorubicin, cyclophosphamide, and ifosfamide. Nevertheless, advanced/metastatic forms displayed poor outcomes [102]. ES family tumors do not benefit from established targeted therapies, emphasizing the imperative to uncover alternative therapeutic strategies. Recently, a phase I/II trial, conducted in a total of 85 patients not preselected for the ES molecular subtype, has shown good tolerability and limited activity of TK216, a small molecule inhibitor of EWS: FLI1 fusion protein inhibiting its function by preventing binding to RNA Helicase A [103].

Sáinz-Jaspeado et al. demonstrated the high expression of EphA2 protein in ES cell lines and patient samples investigating its association with the key membrane trafficking controlling protein CAV-1. CAV-1 contributes to angiogenesis in different tumors [104, 105]. In ES angiogenesis, CAV-1 increases EphA2 activation and signaling influencing its membrane localization [84, 106]. The formation of the EphA2/CAV1 complex also promoted the expression and secretion of bFGF, increasing tumor-induced migration of endothelial cells. These results suggest that in ES, EphA2-induced angiogenesis is dependent on CAV-1 [84]. In another study of the same group, EphA2 was reaffirmed as a significant contributor to the metastatic progression of ES owing to its involvement in cell signaling, mobility, and survival; moreover, the EphA2 phosphorylation at Ser897 was associated with ES aggressiveness [16]. Consistently, silencing EphA2 led to reductions in tumorigenicity, migration, invasiveness, and pulmonary metastatic progression in ES preclinical models. Finally, the knockdown of the metalloproteinase ADAM19, a downstream effector of EphA2 receptor signaling, negatively affects cell migration [16, 107].

Furthermore, our previous study investigated the mRNA expression levels of EphA2 in 12 ES cell lines from the CCLE and its correlation with tissue type, patient characteristics, and clinical outcomes within a cohort of 246 ES patients archived in GEO database. Specifically, we observed a significantly higher expression of EphA2 in tumor samples compared to normal tissues, with higher levels observed in male patients than females [13]. As for OS also for ES, male patients display a worse prognosis than females [108, 109]. These findings suggest that EphA2 might be related to more aggressive tumor behavior. Additionally, targeted inhibition of EphA2 resulted in a notable reduction of ES cell viability [13]. These experimental and computational findings collectively provide compelling evidence to support the hypothesis that targeting EphA2 overexpression may represent a viable therapeutic strategy for evaluation in advanced ES patients.

EphA2 in chondrosarcoma

CS represents a malignant mesenchymal tumor and is the third most common among bone sarcomas across all age groups, yet it predominates in adults. Unlike OS and ES, it mainly occurs during adulthood in patients over the age of 40, with an average incidence of 0.2 cases per 100,000 people per year, both male and female [2, 3]. Most CSs arise as primary, low-grade, locally aggressive, non-metastasizing tumors (grade I) rather than high-grade (grades II-III). The histologic subtypes of CS include conventional, clear cell, mesenchymal, and dedifferentiated CS [3]. Patients with dedifferentiated CS are more likely to develop metastases and have a dismal prognosis with a 5-year overall survival of 7–24%. It is characterized by varied differentiated cells producing chondroid matrices, reflecting its high heterogeneity and association with intricate cytogenetic alterations [88]. Notably, mutations in Isocitrate Dehydrogenase (IDH) genes, specifically IDH1 and IDH2, are frequently observed, along with mutations in genes associated with cancer progression, such as TP53 [110]. CSs generally exhibit resistance to conventional chemotherapy regimens. Standard chemotherapy protocols yield poor results, and in cases in which surgical intervention becomes unviable, the prognosis is extremely poor. Recently, inhibition of IDH1 has shown some degree of activity [99]. Nevertheless, the clinical challenges posed by advanced CSs remain truly unmet in this context. The cornerstone of treatment for CS remains surgery and the result depends on the grade and location. Apart from low-grade CS of the extremities which are treated with extensive intralesional resection associated with local adjuvant treatment (high-speed burr, phenolization or cryotherapy, lavage with a high-pressure pulsatile system, and packing the defect with cement or bone graft). Generally, no adjuvant treatment is recommended in conventional CS due to its low sensitivity to radio and chemotherapy. Some retrospective reports suggest that mesenchymal CS is more chemo-sensitive, and may be considered for adjuvant or neoadjuvant therapy, mainly with Ewing-like regimens [111].

Zhang et al. evaluated the phosphorylation status of 42 RTKs in five CS cell lines showing that EphA2 was highly phosphorylated and constitutively activated in two of them [112]. Nevertheless, the EphA2 expression in CS tumor samples has not yet been extensively studied. In our previous work, we explored the EphA2 gene expression level in 4 CS cell lines belonging to the CCLE and its relationship with clinical and molecular features in a total of 102 CS patients from publicly available datasets. We observed a significantly higher expression of EphA2 in dedifferentiated CS samples with a worse prognosis than in better ones, and EphA2-specific inhibition impinged CS cell viability [13].

Considering these findings, there is a compelling rationale to pursue targeted therapy directed at EphA2 in advanced CS patients. Current therapeutic options for advanced CS remain notably inadequate, emphasizing the need for novel treatment strategies and EphA2 may represent a promising tool.

Therapeutic strategies for targeting EphA2 in solid tumors

A plethora of molecular, genetic, epigenetic, biochemical, pharmacological, and immunotherapeutic strategies targeting EphA2 and its signaling pathways have been developed. This review explored a wide range of interventions, including small molecule inhibitors, monoclonal antibodies, drug or toxin-conjugated antibodies or peptides, chimeric antigen receptor T lymphocytes (CAR-T), and dendritic cell (DC) vaccines investigated in cancer preclinical models and clinical trials, providing valuable insights into their potential efficacy and translation applications also for bone tumors (Fig. 4).

Fig. 4 Schematic diagram summarizing the therapeutic targeting of EphA2 in solid tumors. EphA2 could be exploited as a molecular target ( pink ring): the disruption of its signaling through the inhibition of its expression by siRNAs, miRNAs, YSA-peptides, siRNA-loaded liposomes, and HDAC inhibitors; the promotion of its degradation by monoclonal antibodies, soluble EFNA1, mimetic peptides, EFNA1-Fc, disrupting SAM-SAM interaction peptides; or blocking its activation by EFNA1 antagonists, monoclonal antibodies, tyrosine kinase inhibitors; as a theranostic target (green ring) by using antibodies or peptides conjugates to exotoxins (MEDI547, BT5528, PE38KDEL-1F12, EFNA1-PE38QQR), chemotherapeutic agents (peptides-drug conjugated), nanotherapeutic agents (immunoliposomes or PEGylated nanoliposomes), or radiolabeled probes (radiolabeled antibodies or peptides); or as immunotherapeutic target (blue ring) by DC-vaccines, adoptive cell therapy approaches (CAR-T), or peptides conjugated with immunomodulators (bicyclic peptides). (Created with BioRender.com)

EphA2 as a molecular target

Among the different strategies that have been evaluated to disrupt EphA2 signaling, direct molecular targeting is by far the most investigated one. Indeed, several agents were shown to be able to bind the receptor and interfere with its tumor-promoting effects by different mechanisms such as inhibiting EphA2 expression, promoting its degradation, or blocking its activation [17](Fig. 4).

Inhibiting EphA2 expression

Short interfering RNAs (siRNAs) for gene knockdown have been used for EphA2 silencing and suppressing its expression in human cancer cells. Several studies showed that decreasing the levels of EphA2, through silencing by specific siRNAs, significantly induces antitumor activity, reducing tumor growth and promoting apoptosis, both in in vitro [7] and in vivo models including lung cancer, breast cancer, and glioma [113–116]. We showed that the silencing of EphA2 reduced OS cell proliferation and migration [7] (Fig. 5). Moreover, Zhou et al. demonstrated that combining an EphA2 siRNA with either cisplatin, etoposide, or minustine hydrochloride significantly enhanced the antitumor effect against glioma cells [116]. However, although siRNAs have shown good results in vitro, their activity in vivo was limited by the difficulties of obtaining efficient delivery, cellular uptake, and good stability in body fluids [117]. Aiming to overcome this limitation and improve siRNA delivery, EphA2-specific siRNA was incorporated into neutral 1,2-dioleoyl-sn-glycerol-3-phosphatidylcholine (DOPC) liposomes resulting in an efficient tumor growth reduction in ovarian cancer mouse xenograft models when administered both as a single agent or in combination with paclitaxel [118]. Later, siRNA-DOPC was tested in murine and primate models, showing good safety and feasibility [119], and prompting a phase 1 clinical trial (NCT01591356). A different strategy to improve the EphA2 transcription silencing was proposed by Choi et al. who synthesized the p19-YSA fusion protein, composed of p19 RNA-binding protein and the EFNA1 mimetic YSA peptide as a siRNA delivery strategy. Specifically, YSA is a short amino acid sequence (YSAYPDSVPMMS) that binds with high affinity and selectivity to EphA2, while p19 can bind with high stability to siRNAs, protecting them from external RNAses [120, 121]. More recently, Oner et al. successfully developed a novel, safe, and efficient delivery system based on cationic solid lipid nanoparticles (cSLN) to enhance the bioavailability of EphA2-siRNAs in tumors. They used the dimethyldioctadecylammonium bromide (DDAB) to induce the reduction of the nanoparticle (NP) size and showed that siEphA2-loaded DDAB-cSLN displayed improved cellular uptake and EphA2 silencing [122].

Fig. 5 List of the therapies targeting EphA2 tested preclinically in osteosarcoma, chondrosarcomas, and Ewing sarcomas. (Created with BioRender.com)

Other than siRNA, miRNAs seem to be a good strategy to inhibit the EphA2 expression in many tumors. Different miRNAs are involved in the regulation of the EphA2 oncogene, varying according to the tumor type. At first, Tsouko et al. identified miR-200a as a direct repressor of EphA2 in triple-negative breast cancer, while Li et al. showed the antitumor effect of miR-26b on hepatocellular carcinoma cells [123, 124]. Subsequent research revealed that the overexpression of miR-200c downregulates EphA2 in malignant glioma, breast cancer, and lung carcinoma cells displaying efficient tumor-suppressive properties [125]. Similar tumor suppressive effects were observed with miR-141 in glioma cells, miRNA520d-3p and miR-302b in gastric cancers, and miR-519a on non-small cell lung cancer (NSCLC) cells [126–129]. Conversely, some miRNAs, such as miR-451a and miR-125a‐5p, naturally upregulate the expression of EphA2, making their inhibition a potential strategy to downregulate the oncogene expression. The reduction of miR-451a and miR125a-5p inhibits cell growth and metastasis in bladder carcinoma, and gastric cancer preclinical models, respectively [130, 131].

The overexpression of EphA2 stems from transcriptional activation through regulatory regions controlled by epigenetic regulators. EphA2 is associated with super-enhancers (SEs) activation in tumors [132, 133]. SEs are large clusters of enhancers that recruit multiple transcription factors and are implicated in the transcription of oncogenes [134]. Bioinformatic screening of Cancer Databases identified cancer-associated SEs by analyzing genomic regions with enriched histone 3 lysine 27 acetylation (H3K27Ac) marks. CRISPR technology targeting SE-associated EphA2 genes inhibits cell growth and metastasis. TCF7L2 and FOSL2 transcription factors were found to be recruited at SE-associated EphA2 loci during breast cancer progression [132]. Transcription factors exhibit cell-type-specific functions across different cancer types. Testicular nuclear Receptor 4 regulates EphA2 transcription in hepatocellular carcinoma and controls metastasis [135]. Changes in histone 3 lysine27 acetylation levels correspond to gene transcription regulation, with histone deacetylases (HDACs) playing a pivotal role in this process. HDACs are enzymes that modulate gene expression, making treatment with HDAC inhibitors a viable strategy to impede cancer progression. Notably, EphA2 expression was downregulated in advanced breast cancer following HDAC inhibitor treatment [115]. Furthermore, combining EphA2 and HDAC inhibitors enhanced the anti-tumor effects, underscoring the importance of identifying specific pathways in individual tumors to select optimal therapeutic approaches and develop personalized medicine [136].

Promoting EphA2 degradation

Soluble ligands or monoclonal antibodies (mAbs) that bind to EphA2 may disrupt oncogenic signaling by promoting receptor internalization and degradation [14]. Two independent studies showed that soluble EphA2 ligands in comparison with Fc-mAbs conjugated with EFNA1 induced EphA2 Tyr phosphorylation and proteasomal degradation, displaying tumor-suppressing properties in several tumor types including glioblastoma multiforme (GBM), gastric and breast adenocarcinoma [72, 137]. Additionally, Xu et al. demonstrated that mEA1-EYFP-H10, a fusion protein consisting of monomeric EFNA1 (mEA1) conjugate with an enhanced yellow fluorescent protein and linked to a supported lipid bilayer via a 10-histidine (H10) anchor, induced the Tyr phosphorylation of EphA2, and subsequent degradation [138]. Similarly, two short EFNA1 mimetic peptides, YSA and SWL, have been utilized to specifically target EphA2 LBD, inducing Tyr phosphorylation and signaling activation, albeit with less potency compared to soluble ligands and Fc conjugates [139]. Subsequent structural modifications of these peptides have led to improved derivatives capable of acting as both EphA2 agonist and antagonist and serving as pharmacological carriers [140].

Otherwise, Alves et al., take advantage of the acidic extracellular medium of solid tumors and created a highly soluble conditional peptide, called TYPE7, designed based on the sequence of the TM domain of EphA2, which binds the EphA2 endogenous domain acting as a molecular clamp that envelopes dimers of EphA2. TYPE7 reduced Akt phosphorylation and inhibited cell migration, mimicking the EFNA1 effect [141, 142]. Furthermore, the EphA2 SAM domain at the C-terminus facilitates interactions with regulators of receptor stability such as the lipid phosphatases Ship2 and the adaptor Odin. Ship2 decreased EphA2 endocytosis and consequent degradation, producing pro-oncogenic outcomes. In this setting, Mercurio et al. first discovered that the Ship2-SAM domain interaction promotes pro-oncogenic effects, identifying the peptide region involved in this interaction [143]. By computational and experimental approaches, they developed and tested several cyclic peptides that interfered with this complex and showed high serum stability and enhanced efficacy [144, 145]. Another strategy to modulate EphA2 activation regards the development of mAbs and other agonists acting as EFNA1 mimetics and eventually inducing receptor internalization and degradation [14]. For example, Carles-Kinch et al. identified EA1.2 mAb which recognizes specific epitopes of the EphA2 extracellular domain, inhibiting metastatic features on breast cancer cells, while sparing normal breast epithelial cells [146]. Different mAbs displayed similar results in several solid tumors. Coffman et al. showed that EA2 and B233 EphA2-specific mAbs promote EphA2 phosphorylation and degradation in breast and lung cancer cells, reducing cell growth in mice models, while Ansuini et al. developed and tested IgG25, another specific EphA2 mAb that promotes receptor endocytosis and subsequent degradation in pancreatic cancer in vitro and in vivo models, particularly reducing EphA2 protein levels and the phosphorylation of FAK on Tyr576 [147, 148]. Similarly, Jackson et al. generated an EphA2-specific fully humanized IgG1 mAb 1C1 able to induce receptor phosphorylation, internalization, and degradation [149]. DS-8895a is another new afucosylated humanized specific mAb which recognizes the extracellular juxtamembrane region of EphA2, interacting with both the full-length and truncated forms of the receptor. DS-8895a induces antibody-dependent cellular cytotoxicity, inhibiting tumor growth in both in vitro and in vivo models of breast and gastric cancers. Moreover, it potentiates the antitumor effect of cisplatin when administered in combination [150]. More recently, Sakamoto et al. produced three mAbs recognizing EphA2, showing that SHM16 inhibited migration and invasion of melanoma cells efficiently [151].

Blocking EphA2 activation

Agents binding to EphA2 or its ligand EFNA1 act as antagonists and suppress signaling, inhibiting Eph-Ephrin interaction or directly the receptor activity [17]. Dobrzanski et al. showed that the administration of EphA2/Fc soluble receptors, composed of EphA2 fused with the Fc region of human IgG1 antibody, functions as a decoy for activating ligands preventing their binding, and blocking the EphA2 signaling, thereby reducing tumor cell growth and invasiveness in preclinical models of pancreatic carcinoma [152]. Meanwhile, Ansuini et al. developed and tested a specific EphA2 mAb called IgG28 that impedes the binding to EFNA1, thereby impairing tumor vascularization in preclinical models of pancreatic cancer [148].

Another strategy was based on lithocholic acid (LCA), a secondary bile acid produced from chenodeoxycholic acid by colon bacterial activity. LCA is a competitive and reversible EphA2 antagonist that inhibits EphA2-EFNA1 interaction, blocking the receptor phosphorylation and activation; however, it does not discriminate between different combinations of Eph-Ephrin binding [153]. Several attempts were made to obtain and even increase the selectivity for EphA2 [154–157]. First, Giorgio et al. showed that LCA inhibited EphA2 phosphorylation in prostate and colon adenocarcinoma cell lines, without affecting other tested receptor tyrosine kinases [153]. They also discovered that the carboxylate group of LCA is critical for disrupting the EFNA1 ligand binding to EphA2 and identified the cholanic acid as a more competitive inhibitor than LCA [154]. Later, they synthesized a set of LCA derivatives that efficiently antagonized EphA2 in prostate cancer cells at low µM concentrations [155–157]. Finally, they designed and tested UniPR129, the L-homo-tryptophan conjugate of LCA that disrupted EphA2-EFNA1 interaction, inhibiting EphA2 activation and angiogenesis in prostate cancer cells [158]. Another derivative of 3β-hydroxy-D5-cholenic acid and L-tryptophan called UniPR1331 was active at low molecular concentration, showed good tolerability in GBM preclinical models, and potentiated the antitumor effect of bevacizumab when administered in combination [159]. Tognolini’s group efficiently demonstrated that the structural requirements for a small molecule to bind different receptors, among which Epha2, Farnesoid X receptor, and the G-protein-coupled receptor 5, are similar [160]. They selected and tested different Farnesoid X receptor agonists, among which Cilofexor, showing that they bind specifically and reversibly to EphA2 and interfere with EphA2 oncogenic phosphorylation in prostate adenocarcinoma cells [160].

Other researchers focused on tyrosine kinase inhibitors (TKI) and their potential to bind the EphA2 inner part, preventing its downstream signaling. Dasatinib, an oral multi-TKI, was the first studied in this context [161–163]. Chang et al. observed that, after EFNA1 stimulation, dasatinib inhibited EphA2 phosphorylation [163]. In addition, Buettner et al. showed that dasatinib inhibited the EphA2 tyrosine kinases activity, blocking migration and invasion, but not proliferation and survival, in human melanoma cell lines [161], while Ishigaki et al. observed that dasatinib exclusively inhibited the proliferation of EphA2-positive small-cell lung cancer (SCLC) cells, suggesting feasibility for clinical settings [114]. Dasatinib, either alone or in combination with chemotherapy, has been assessed in several clinical trials for advanced solid tumors (NCT00162214, NCT00792545), including SCLC (NCT00470054), squamous cell carcinoma (NCT00563290), endometrial cancer (NCT01440998) and in combination with radiotherapy in GBM (NCT00895960). Notably, this inhibitor has shown a broad range of targets making it challenging to interpret biological and clinical data [164–166]. However, these findings guided a chemical proteomics approach to designing and synthesizing new EphA2 inhibitors based on dasatinib structure. This approach seeks to exploit the ATP and the ribose pockets as binding epitopes in EphA2 kinase, improving its targeting profile. Compounds with an improved selectivity profile and potent anti-proliferative effect against GBM were obtained [167]. Similarly, Ho et al., using an orthogonal biological phenotypic screening approach, identified a group of newly synthesized benzylidene-indolinones able to inhibit multiple tyrosine kinases such as IGF-1R, Tyro3, and EphA2 phosphorylation. Among different candidates, they selected the most effective TKI which displayed a good safety profile and potent anti-proliferative, anti-migratory, and pro-apoptotic activities in hepatocellular carcinoma preclinical models [168]. Sitravatinib (MGCD516) is another multi-TKI inhibiting EphA2 [169]. Patwardhan et al. showed that this molecule promotes the blockade of RTK phosphorylation and induced tumor growth suppression in different sarcoma models, among which OS and ES, acting also in TKI-resistant models (Fig. 5) [170]. Based on these preclinical findings, a phase 1 clinical trial (NCT02219711) was conducted by Bauer et al. in patients with advanced solid tumors to evaluate its safety, pharmacokinetic, metabolism, pharmacodynamic, and clinical activity profiles, showing feasibility with only limited manageable side effects in these patients [171]. Several other clinical trials are currently ongoing to test the efficacy of sitravatinib in different types of cancers such as NSCLC (NCT03906071), liposarcoma (NCT02978859), squamous cell carcinoma (NCT03575598) and urothelial carcinoma (NCT03606174), as monotherapy or combination therapy.

Speaking of selective TKI targeting EphA2, ALW-II-41-27 showed promising antitumor effects in preclinical models of lung cancers, inducing time and dose-dependent apoptosis and tumor regression in NSCLC models, among which the EGFR-inhibitor-resistant ones, and inhibiting exclusively the proliferation of EphA2-positive SCLC models [113, 114, 172]. Furthermore, ALW-II-41-27 has been administered in combination with cetuximab reverting both primary and acquired drug resistance and resulting in proliferation inhibition, apoptosis induction, and tumor growth blockade in preclinical models of colorectal cancer [114]. This inhibitor is also effective in nasopharyngeal carcinoma cells, and in cervical cancer cells, reducing tumor growth, cell proliferation, migration, and invasion [173–175]. We also explored the effect of ALW-II-41-27 in OS, CS, and ES preclinical models, showing that it inhibited cell growth in a dose-dependent manner (Fig. 5) [13].

EphA2 as a target for theranostic applications

The overexpression of EphA2 in tumor cells and its relatively low expression level in normal tissue makes EphA2 an ideal target for tumor-specific delivery of chemotherapy or toxins while sparing healthy cells [14, 38]. Various types of antibodies-drug or peptides-drug conjugates have been developed and tested to hit EphA2-expressing tumor cells (Fig. 4).

Peptide/antibody exotoxin-conjugates

Derivatives of the highly cytotoxic exotoxin A of Pseudomonas aeruginosa were developed and conjugated with EFNA1 or with fragments of mAb recognizing EphA2 showing antitumor effects in preclinical models with limited side effects [176, 177]. In addition, Sakamoto et al. used the SHM16 mAb to deliver the saporin toxin in melanoma cells [151].

Another approach involves the conjugation of anti-EphA2 1C1 mAb with the toxin monomethyl auristatin phenylalanine (MMAF) via a stable maleimidocaproyl linker, known as MEDI-547 [149]. Upon EphA2 binding, this conjugate undergoes internalization and enzymatic cleavage, releasing MMAF that binds to tubulin, inhibiting its polymerization and inducing cell cycle arrest and apoptosis. MEDI-547 triggers activation of caspase-3/7 and cell death, EphA2 degradation, and tumor growth inhibition with minimal side effects in tumor preclinical models [178, 179]. Despite these encouraging results, in a phase I clinical trial (NCT00796055) testing MEDI-547, severe dose-limiting toxicity was observed arresting any further development of this strategy [180]. Then, novel EphA2-selective bicycle toxin-conjugates (BTC) were developed by Bicycle Therapeutics to avoid side effects. Mudd et al. used a phage display selection to generate a BTC with another potent microtubule inhibitor, the cytotoxin mertansine (DM1) via a cleavable linker, able to bind the EphA2-LBD at a low nanomolar range. After chemical optimization, they showed that it displayed potent antitumor activity and was well tolerated in xenograft models [181]. The most promising is BT5528 composed of the antimitotic agent MMAE linked via a chemical scaffold, capable of binding to EphA2 with high affinity and stability, avoiding off-target effect. Compared to MEDI-547, Bicycle toxins are much smaller and display a “fast-in and fast-out” mechanism of action exposing much less drug to the normal tissues [182]. MEDI-547 and BT5528 both carrying MMAE were compared: the BTC displayed potent antitumor activity avoiding hematologic adverse effects in animal models first, and in humans later, showing manageable side effects [182]. Moreover, the administration of BT5528, alone or in combination with nivolumab, in patients with solid tumors is ongoing in a phase I/II clinical trial (NCT04180371).

Peptide/antibody chemotherapy conjugates

The conjugation of peptides or antibodies that selectively bind EphA2 and induce its internalization provides a vehicle for targeting chemotherapeutic agents specifically to cancer cells sparing healthy tissues. Recently, Wang et al. conjugated the EphA2 agonist short peptide YSA with the cytotoxic agent paclitaxel (PTX) showing that it is significantly more effective than chemotherapy alone in a prostate cancer xenograft model [183]. Later, they optimized the drug-like properties of this delivery system by introducing non-natural amino acids, synthesizing, and testing two new PTX-conjugates EphA2 targeting peptides. In particular, dYNH-PTX displayed higher stability in mouse serum and significantly reduced tumor volume in prostate and renal cancer preclinical models [184]. Next, they investigated the chemical determinants responsible for the stability and degradation of these agents in plasma and introduced modifications to obtain more long-lived and more effective agents [185]. Despite their efficacy, these short peptides are often degraded and eliminated too rapidly in vivo. Therefore, Wu et al. developed 123B9-PTX, a novel tumor-homing agent that targets the EphA2-LBD, conjugated with PTX via a stable linker which displayed good efficacy in a pancreatic cancer xenograft and melanoma lung colonization and metastases models [186]. To overcome the limit due to the high concentrations required, they also developed a dimeric version of this compound (123B92–L2–PTX) which acted at nanomolar concentrations, targeting circulating tumor cells and inhibiting lung metastasis in breast cancer models [187]. The same strategy was adopted to conjugate gemcitabine with EphA2 targeting agents, developing YNH-L2-Gem and 123B9-L2-Gem, which showed good results in pancreatic cancer models [188]. Finally, more recently, Baggio et al. developed Targefrin-PTX, a novel agent targeting the EphA2-LBD that efficiently delivered to pancreatic cancers xenograft models reducing tumor volume and circulating tumor cells [189].

Peptide/antibody nanotherapeutic agent conjugates

The abovementioned peptides and antibodies can also be conjugated with PEGylated nanoliposomes and loaded with different drugs, such as the MEK inhibitor trametinib and the chemotherapeutic agent doxorubicin [190, 191]. This delivery approach allows drug release after internalization in tumor cells expressing EphA2, reducing circulating free-drug, and minimizing the off-target toxicity [190]. Fu et al. showed that the YSA-trametinib-loaded PEGylated nanoliposomes (YTPL) complex displayed the desired cytotoxicity against melanoma cells with higher uptake in vemurafenib-sensitive cells compared to its resistant counterpart [190]. Similarly, Haghilralsadat et al. showed that the YSA-doxorubicin-loaded PEGylated nanoliposomes (YSA-L-DOX) efficiently targeted the EphA2 receptor on human SAOS-2 OS cell line, promoting dose reduction and a higher cytotoxic activity (Fig. 5) [191]. Later, they developed a dual-targeted approach which consisted of targeting OS cell lines both extracellularly, against EphA2, and intracellularly against JNK-interacting protein 1 (JIP1) using YSA-PEGylated cationic liposomes loaded with doxorubicin and siRNA against JIP1 protein (YSA-L-JIP1siRNA-DOX). This strategy efficiently induced a reduction of JIP1 expression and the induction of apoptosis at the cellular level [192]. More recently, in collaboration with Carofiglio et al., we proposed to conjugate and with YSA peptide the iron-droplet zinc oxide (ZnO) nanoparticles coated with a 3 C lipidic shell and conjugated (FZ-3 C-YSA-NPs), to potentiate the specific targeting of OS. This construct triggers a specific cytotoxic effect that suppresses OS cell growth by increasing reactive oxygen species only when remotely activated by a mechanical pressure stimulation through ultrasound irradiation (Fig. 5) [193].

Another type of antibody-directed nanotherapeutics is MM-310. This is constituted by immunoliposomes loaded with the precursor form of docetaxel and conjugate with the anti-EphA2 scFv-3 peptide. Kamoun et al. tested the preclinical efficacy of MM-310 in bladder cancer xenograft models, both as a monotherapy and in combination with gemcitabine, showing that the combination improved tumor growth control [194]. Moreover, they studied the combination activity of MM-310 with the immune checkpoint inhibitors anti-PD1 and anti-PD-L1 in breast, colon, lung carcinoma, and in fibrosarcoma syngeneic mouse models, demonstrating the synergistic and immunomodulatory effects of the combination, mainly in breast cancer tumor models [195]. Based on these findings, a phase I clinical trial is ongoing to study the maximum tolerated dose and the safety profile of MM-310 in patients with advanced solid tumors, including soft tissue sarcoma (NCT03076372) [196].

Peptide/antibody imaging or therapeutic radiolabeled probe conjugates

Thanks to its high expression in both cancer cells and tumor vasculature compared to normal tissue, EphA2 can also be used as a target to deliver imaging agents for diagnostic and therapeutic purposes [197]. In this context, several specific probes consisting of radiolabeled peptides or antibodies binding EphA2 were developed for molecular imaging [198].

The first quantitative radioimmuno-positron emission tomography (PET) imaging of EphA2 was performed by Cai et al. in tumor-bearing mice, using the 64Cu-DOTA-1C1 compound, which consists of the 1C1 EphA2 antibody labeled with copper-64 (64Cu) through the chelating agent DOTA (1,4,7,10-tetraazacyclododecane N, N′,N″,N″′-tetra-acetic acid). This tracer showed promising results for clinical purpose investigation [199]. Similarly, Puttick et al. conjugated the 4B3 EphA2 antibody, labeled with 64Cu, with the chelating agent NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) to perform PET imaging. They observed that 64Cu-NOTA-4B3 effectively delineates tumor burden, displaying both qualitatively and quantitatively better high-contrast images compared to other clinical standards imaging tools, in GBM mice models [200]. Later, Pyo et al. conjugated the same compound with another EphA2 antibody, E1, and observed that 64Cu-NOTA-E1 tracer displayed high tumor uptake and retention in human cancer prostate cells, rapid clearance in xenograft mice models and low background values in other tissues [201]. In addition, Burvenich et al. labeled another EphA2-specific antibody, DS-8895 A, with three different radio-isotypes: iodine-125 (125I), indium-111 (111In) and zirconium-89 (89Zr). They showed that 111In and 89Zr radio-conjugates displayed the highest uptake in EphA2-expressing tumors because of their entrapment inside the cell; on the contrary, 125I resulted in the lowest tumor uptake due to its internalization, translocation to lysosomes and subsequent degradation which release 125I-catabolites from the cells. Moreover, they observed that molecular imaging of DS-8895a tumor uptake, in particular using the [89]Zr-Df-Bz-NCS-DS-8895a compound, allows noninvasive measurement of EphA2 expression and determination of its saturation in xenograft models [202]. These considerations lead this compound in phase-I bio-imaging clinical trials, evaluating its dose assessment and patient response, showing that it is safe and well tolerated in patients with advanced solid tumors (NCT02004717; NCT02252211) [203, 204]. In the phase Ib study of DS-8895 A in patients with advanced/metastatic EphA2-positive cancers, no dose-limiting toxicities or treatment-related adverse events were reported. Observed non-drug related, treatment-emergent adverse events (grade ≤ 2) included fatigue (n = 3, 43%), diarrhea (n = 2, 29%), thrombocytopenia (n = 2, 29%), and decreased appetite (n = 2, 29%) [204].

Furthermore, Furukawa et al. recently developed and tested a novel imaging tracer to perform single-photon emission computed tomography (SPECT) of the EphA2 receptor. They conjugated the EphA2-230-1 mAb with the bifunctional chelator p-SCN-BnDTPA and labeled it with [111In], evaluating its affinity and pharmacokinetics. This [111In]In-BnDTPA-EphA2-230-1 tracer exhibited high tumor accumulation and successfully showed the tumor during the SPECT imaging on GBM mice models [205].

In analogy, radiolabeled peptides could be used for diagnostic imaging and eventually targeted radiotherapy. For instance, Pretze et al. synthesized [18 F]AFP-SWL, a new radiolabeled peptide consisting of the EphA2 specific SWL peptide conjugated with the bioorthogonal radiolabeling building block [18 F]AFP (1-(3-azidopropyl)-4-(3-fluoropropyl)piperazine). They were the first to perform a radio-pharmacological characterization of this radiotracer, evaluating its metabolic stability [206]. However, a more promising tracer was developed by Liu et al. conjugating technetium-99 m (99mTc) with the same peptide, resulting in the 99mTc-HYNIC-SWL tracer which displayed rapid blood clearance by renal excretion in lung cancer and melanoma in vivo preclinical models [207]. Moreover, Furukawa et al. developed [123I]ETB, a SPECT imaging tracer for the EphA2 receptor which consists of an ALW-II-4127 EphA2 inhibitor derivative (ETB), labeled with gamma-emitting iodine-123 (I-123), showing that it selectively bound and inhibited EphA2 and also revealed an efficient tumor uptake in GBM mice models [208].

EphA2 as a target for immunotherapy

The extraordinary developments in immunotherapy make the preferential expression of EphA2 in solid tumors an attractive possible target for anticancer immunotherapy. Indeed, thanks to its membrane expression, EphA2 can be a good target for vaccines and adoptive cell therapy approaches, such as the CAR-T strategy [209] (Fig. 4).

EphA2 redirected CAR-T

Nowadays, a very promising immunotherapy strategy is based on autologous T lymphocytes extracted from patient blood samples, genetically engineered ex vivo to express artificial chimeric antigen receptors (CAR) recognizing a specific tumor antigen and then re-infused into the patient to obtain a T-cell dependent tumor cell killing. The definition of a selective and tumor-specific target is crucial to avoid side effects [210]. CAR-T cells specifically directed against EphA2 have been developed and studied against different tumors, such as NSCLC, esophageal squamous cell carcinoma (ESCC), GBM, and pediatric bone sarcomas [211–214]. At first, Chow et al. developed EphA2-specific T cells constituted by EphA2-CAR with a CD28-ζ endodomain which induced a potent anti-cancer activity on GBM cells and the regression of GBM xenograft in SCID mice, prolonging their survival [213]. Then, Yi et al. generated and compared different EphA2-specific CAR-T against GBM models, showing that T cells expressing both the endo-domains CD28.ζ and 41BB.ζ CARs with short spacers efficiently improve the CAR-T cell function, compared to incorporating the 41BB domain into CD28.ζ CARs [215]. Similarly, a second generation of efficient specific EphA2.CAR-T with the co-stimulatory receptor 4-1BB was developed and tested in NSCLC and ESCC in vitro and in vivo models [211, 212]. Hsu et al. tested EphA2 CAR-T therapy against OS and ES, demonstrating its anti-tumor activity in metastatic murine models both in vitro and in vivo (Fig. 5) [214]. Moreover, Lange et al. recently developed GM18, a novel CAR consisting of the GM-CSF receptor extracellular domains and the IL18 transmembrane domains, that links CAR-T cell activation to MYD88 signaling. It was developed to sustain the CAR-T cell function after repeated exposure to tumor cells, by activating an antigen-dependent autocrine loop. They showed that CAR.GM18-T cells significantly increase the expansion and production of cytokines in vitro and induce tumor regression in ES and OS in vivo models, compared to standard CAR-T (Fig. 5) [216]. Finally, a recent advancement in CAR-T therapy involves the development of TanCAR-T cells to enhance the treatment of GBM both in vitro and in vivo. TanCAR-T cells are engineered with a tandem arrangement of IL13 (4MS) and EphA2 scFv, as well as both targets when present on cancer cells. Importantly, TanCAR-T cells are programmed to spare normal cells that express only the IL13Ra1/IL4Ra receptor, thereby minimizing off-target effects and enhancing the specificity of the therapy [217].

In the first clinical trial with EphA2-redirected CAR-T cells, the reported toxicities in the first 3 treated patients were pulmonary edema with cytokine release syndrome in 2 out of 3 patients. This might be due to the physiological expression of EphA2 by lung epithelial cells [218]. Unfortunately, our relatively little knowledge on EphA2 expression by adult healthy tissues further complicates our ability to predict which other organ sites could be affected by on-tumor, off-target side effects.

DC-vaccines

Despite its physiological expression in normal tissues, the relatively low distribution of the EphA2 receptor in adult cells, compared to cancer cells, renders it an almost ideal target for vaccine-based strategies. In this scenario, DC-based vaccines emerge as a promising therapeutic approach in cancer immunotherapy since they promote antitumor response taking advantage of each patient’s immune system [219]. Indeed, DCs are proficient antigen-presenting cells specialized to capture, process, and present antigens on major histocompatibility complex molecules [220]. Moreover, DCs play key roles in the communication between innate and adaptive immunity and are responsible for the antigen-specific adaptive immune response initiation stimulating both helper T cells and cytotoxic T lymphocytes (CTLs) that recognize specifically tumor cells [221]. The first evidence to support the potential of EphA2-based vaccine therapies was realized by Hatano et al., they demonstrated that EphA2-derived peptide vaccination promoted immunity and induced therapeutic anti-tumor effects in mice models. Furthermore, they observed that this vaccination effectively prevented tumor establishment or growth in EphA2-positive syngeneic glioma, sarcoma, and melanoma models and that EphA2 vaccines could also be directed to EphA2-negative target cells, targeting tumor-associated vascular endothelial cells expressing EphA2, as different tumor-associated antigens [222, 223]. In addition, to improve the CTL-mediated immune response against glioma cells, Chen et al. developed and tested a novel vaccine containing EphA2883–891 peptide and LIGHT plasmid in HLA-A2 transgenic mice. They observed that this vaccine induced a robust cellular anti-tumor immunity against U251 glioma cells and inhibited tumor growth [224]. As well, Yeung et al. demonstrated that an increased expression of tumor-associated antigens such as EphA2, IL-13Rα2, and Survivin, allowed the basis for the utilization of an established multiple peptide vaccine in pediatric and adult ependymomas [225]. Therefore, Pollack et al. worked on a pilot study of subcutaneous vaccinations using these glioma-associated antigens epitope peptides emulsified in Montanide-ISA-51. They showed good tolerability and immunogenic activity with preliminary evidence of efficacy ascribing this as a promising strategy [226]. The results obtained with vaccines in glioma tumors were later confirmed in other models. Yamaguchi et al. evaluated the immunotherapy efficacy of DCs pulsed with EphA2-derived peptide on murine MC38 colon cancer models. They demonstrated that this strategy inhibited tumor growth in EphA2-positive colon cancer xenografts but not in EphA2-negative melanoma ones. Moreover, they observed that natural killer cells, but not CD4 + and CD8 + T lymphocytes, were necessary for immunizations and the vaccine had long-term anti-tumor immunity [227, 228]. Additionally, the researchers observed heightened tumor-specific CTL activity in both colon cancer and melanoma mice models [229]. Therefore, EphA2-DCs and EphA2-NPs vaccines warrant further studies in selected EphA2-expressing tumors. Furthermore, in a recent phase II trial, Storkus et al. demonstrated that dasatinib is a potent adjuvant in specific vaccination against overexpressed and non-mutated tumor blood vessel antigens, including EphA2. The active recruitment of T cells in tumor sites lowered myeloid-derived suppressor cells and regulatory T cell abundance extending the patient’s overall survival. This vaccination combined with dasatinib was safe and resulted in immunologic and clinical responses in melanoma patients [230].

Peptide/antibody immunomodulator conjugates

Another strategy to take advantage of EphA2 specificity is the stimulation of the immune cells exclusively at the tumor site, exploiting a specific binding to EphA2 tumor cells and immune cells infiltrating the nearby microenvironment. BCY12491, a tumor-targeted immune cell agonist (TICA) exemplifies a new class of fully synthetic immunomodulators consisting of two bicyclic peptides, constricted each other, targeting respectively EphA2 as tumor antigen, and a co-stimulatory molecule CD137 or 4-1BB, a member of the tumor necrosis factor receptor superfamily. Upadhyaya et al. showed that BCY12491 is a highly specific and potent immune cell stimulator through CD137 agonism, in EphA2-overexpressing tumors that avoid systemic activation. Preclinical data confirmed that BCY12491 showed potent EphA2-dependent immunomodulatory activity in vitro and induced local tumor regression, complete responses, immunogenic memory, and significant modulation of the tumor immune microenvironment in preclinical syngeneic mouse models [231]. These findings provide a strong rationale to further develop the first-in-class Bicycle TICAs to potentially treat EphA2-expressing cancers.

Conclusions

In conclusion, targeting EphA2 in bone sarcomas is a promising therapeutic strategy due to its highly tumor-specific expression and pivotal role in tumor progression and metastasis. The development of advanced drug delivery systems, such as NP-based carriers, antibody-drug conjugates, small molecule inhibitors, and gene therapy approaches, enhances the precision and efficacy of EphA2-targeted therapies. These methods not only improve drug delivery to the tumor site but could also help minimize systemic toxicity. However, given the lack of data on EphA2 protein expression in adult normal tissues [38], considerations on potential on-target, off-tumor effects should be considered cautiously. Despite its benefits, targeting EphA2 and its delivery system might lead to off-target effects, immune reactions, and toxicity. Disrupting normal cellular functions of EphA2 and the potential development of resistance are additional concerns. Hematologic toxicity, affecting blood cell counts and bone marrow function, is also a risk. Ongoing research and clinical trials are crucial to optimize these therapies, addressing the challenges and ensuring safe and effective treatment options for patients with bone sarcomas. EphA2 overexpression in bone tumors compared to normal tissues and its involvement in key tumor processes (e.g., proliferation, migration, and angiogenesis) supports its validity as a therapeutic target. EphA2 targeting can work synergistically with other treatments, potentially lowering the risk of resistance development, which typically ensues with all single-agent targeted treatments. Continued investigation into the mechanisms of EphA2 in cancer biology and the refinement of delivery methods will be key to realizing the full therapeutic potential of EphA2 targeting bone sarcomas. Dedicated clinical trials of EphA2 targeting in the diverse histotypes of each bone sarcoma are still missing, and the study of EphA2 protein expression in the different bone sarcoma subtypes can be useful for predicting the efficacy of EphA2 targeting strategies. These strong preclinical and early clinical studies of multifaceted targeting of EphA2 give rise to encouraging results of efficient novel therapeutic strategies against EphA2-expressing tumors. The distinct expression patterns of EphA2 and its pivotal role in promoting tumor progression render this protein an attractive target for therapy across various cancers. This includes advanced bone sarcomas which remain challenging to treat and lacks effective therapeutic options so far. These findings open the way toward novel therapeutic avenues for addressing these aggressive, rare, and currently “drug-orphan” diseases.

Acknowledgements

The authors are grateful to Prof. Michele De Bortoli and Dr. Giovanni Grignani for their helpful discussion and continuous support.

Authors Contribution

Conceptualization: G.G. and Y.P.; original draft and figure preparation: G.G.; writing-review and editing, C.T., A.M, S.C., and Y.P.; supervision and funding acquisition: Y.P. All authors have read and approved the final version of the manuscript.

Funding

This work was supported by Italian Ministry of Health, Ricerca Corrente 2024 and Ministero della Salute- Ricerca Finalizzata- Giovani Ricercatori GR-2016-02362726 to YP (UO2). Biorender.com license was provided by the Department of Clinical and Biological Sciences (grant RILO 2021_01) to Y.P.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethical approval

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Abbreviations

EphA2 Ephrin Type-A Receptor 2

OS Osteosarcoma

ES Ewing sarcoma

CS Chondrosarcoma

RTKs Receptor tyrosine kinases

Eph Erythropoietin-producing hepatocellular

LBD Ligand-binding domain

EGF Epidermal growth factor

FN Fibronectin

TM Transmembrane

TK Tyrosine kinase

SAM Sterile alpha motif

RBD Receptor-binding domain

GPI Glycosylphosphatidylinositol

Tyr Tyrosine

EFNA1 Ephrin-A1

TNF Tumor necrosis factor

ERKs Extracellular signal -regulated kinases

FAK Focal adhesion kinase

Rho G Ras homolog gene family, member G

CAF Cancer associated fibroblast

CAV-1 Caveolin-1

LMW-PTP Low molecular weight phospho-tyrosine phosphatase

bFGF Basic FGF

CCLE Cancer cell line encyclopedia

GEO Gene expression omnibus

EWSR1 RNA-binding protein EWS

STAG2 STAG2 cohesin complex component

TP53 Tumor protein 53

CDKN2A Cyclin-dependent kinase inhibitor 2 A

KDR Kinase insert domain receptor

STK11 Serine/threonine kinase 11

MLH1 DNA mismatch repair protein Mlh1

KRAS Kirsten rat sarcoma virus

PTPN11 Tyrosine-protein phosphatase non-receptor type 11

IDH Isocitrate dehydrogenase

CAR-T Chimeric antigen receptor T lymphocytes

DC Dendritic cell

DOPC 1,2-Dioleoyl-sn-glycerol-3-phosphatidylcholine

cSLN Cationic solid lipid nanoparticles

NP Nanoparticle

NSCLC Non-small cell lung cancer

DDAB Dimethyldioctadecylammonium bromide

SEs Super-enhancers

HDACs Histone deacetylases

GBM Glioblastoma

mAbs Monoclonal antibodies

mEA1 Monomeric EFNA1

LCA Lithocholicacid

TKI Tyrosine kinase inhibitors

SCLC Small-cell lung cancer

MMAF Monomethyl auristatin phenylalanine

BTC Bicycle toxin-conjugated

PTX Paclitaxel

YTPL YSA-trametinib-loaded PEGylated nanoliposomes

YSA-L-DOX YSA-doxorubicine-loaded PEGylated nanoliposomes

PET Positron emission tomography

DOTA 1,4,7,10-Tetraazacyclododecane N, N′,N″,N″′-tetra-acetic acid

NOTA 1,4,7-triazacyclononane-1,4,7-triacetic acid

125I Iodine-125

111In Indium-111

89Zr Zirconium-89

SPECT Single-photon emission computed tomography

AFP 1-(3-azidopropyl)-4-(3-fluoropropyl)piperazine

99mTc Technetium-99 m

ETB Epha2 inhibitor derivative

I-123 Iodine-123

TICAs Tumor-targeted immune cell agonists

ESCC Esophageal squamous cellcarcinoma

CTLs Cytotoxic T lymphocytes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Casali PG Bielack S Abecassis N Aro HT Bauer S Biagini R Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 2018 29 Suppl 4 iv79 95 10.1093/annonc/mdy310 30285218
Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, et al. Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv79–95.30285218 10.1093/annonc/mdy310
2. Redondo A Bagué S Bernabeu D Ortiz-Cruz E Valverde C Alvarez R Malignant bone tumors (other than Ewing’s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS) Cancer Chemother Pharmacol 2017 80 6 1113 31 10.1007/s00280-017-3436-0 29038849
Redondo A, Bagué S, Bernabeu D, Ortiz-Cruz E, Valverde C, Alvarez R, et al. Malignant bone tumors (other than Ewing’s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS). Cancer Chemother Pharmacol. 2017;80(6):1113–31.29038849 10.1007/s00280-017-3436-0
3. Board WCoTE. Soft tissue and Bone Tumours. WHO Classification of Tumours tE; 2020.
4. Meyers PA Schwartz CL Krailo M Kleinerman ES Betcher D Bernstein ML Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate J Clin Oncol 2005 23 9 2004 11 10.1200/JCO.2005.06.031 15774791
Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23(9):2004–11.15774791 10.1200/JCO.2005.06.031
5. Meyers PA Schwartz CL Krailo MD Healey JH Bernstein ML Betcher D Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival–a report from the children’s Oncology Group J Clin Oncol 2008 26 4 633 8 10.1200/JCO.2008.14.0095 18235123
Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival–a report from the children’s Oncology Group. J Clin Oncol. 2008;26(4):633–8.18235123 10.1200/JCO.2008.14.0095
6. Pignochino Y Dell’Aglio C Inghilleri S Zorzetto M Basiricò M Capozzi F The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma BMC Cancer 2015 15 374 10.1186/s12885-015-1363-1 25952930
Pignochino Y, Dell’Aglio C, Inghilleri S, Zorzetto M, Basiricò M, Capozzi F, et al. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. BMC Cancer. 2015;15:374.25952930 10.1186/s12885-015-1363-1
7. Chiabotto G, Grignani G, Todorovic M, Martin V, Centomo ML, Prola E et al. Pazopanib and Trametinib as a synergistic strategy against Osteosarcoma: preclinical activity and molecular insights. Cancers (Basel). 2020;12(6).
8. Fioramonti M Fausti V Pantano F Iuliani M Ribelli G Lotti F Cabozantinib affects Osteosarcoma Growth through a direct effect on Tumor cells and modifications in bone microenvironment Sci Rep 2018 8 1 4177 10.1038/s41598-018-22469-5 29520051
Fioramonti M, Fausti V, Pantano F, Iuliani M, Ribelli G, Lotti F, et al. Cabozantinib affects Osteosarcoma Growth through a direct effect on Tumor cells and modifications in bone microenvironment. Sci Rep. 2018;8(1):4177.29520051 10.1038/s41598-018-22469-5
9. Grignani G Palmerini E Ferraresi V D’Ambrosio L Bertulli R Asaftei SD Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial Lancet Oncol 2015 16 1 98 107 10.1016/S1470-2045(14)71136-2 25498219
Grignani G, Palmerini E, Ferraresi V, D’Ambrosio L, Bertulli R, Asaftei SD, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015;16(1):98–107.25498219 10.1016/S1470-2045(14)71136-2
10. Pignochino Y Dell’Aglio C Basiricò M Capozzi F Soster M Marchiò S The combination of Sorafenib and Everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models Clin Cancer Res 2013 19 8 2117 31 10.1158/1078-0432.CCR-12-2293 23434734
Pignochino Y, Dell’Aglio C, Basiricò M, Capozzi F, Soster M, Marchiò S, et al. The combination of Sorafenib and Everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin Cancer Res. 2013;19(8):2117–31.23434734 10.1158/1078-0432.CCR-12-2293
11. Grignani G Palmerini E Dileo P Asaftei SD D’Ambrosio L Pignochino Y A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study Ann Oncol 2012 23 2 508 16 10.1093/annonc/mdr151 21527590
Grignani G, Palmerini E, Dileo P, Asaftei SD, D’Ambrosio L, Pignochino Y, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012;23(2):508–16.21527590 10.1093/annonc/mdr151
12. Pignochino Y Grignani G Cavalloni G Motta M Tapparo M Bruno S Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways Mol Cancer 2009 8 118 10.1186/1476-4598-8-118 20003259
Pignochino Y, Grignani G, Cavalloni G, Motta M, Tapparo M, Bruno S, et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer. 2009;8:118.20003259 10.1186/1476-4598-8-118
13. Giordano G, Merlini A, Ferrero G, Mesiano G, Fiorino E, Brusco S et al. EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing’s Sarcoma and Chondrosarcoma. Cells. 2021;10(11).
14. Binda E Visioli A Giani F Lamorte G Copetti M Pitter KL The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas Cancer Cell 2012 22 6 765 80 10.1016/j.ccr.2012.11.005 23238013
Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL, et al. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell. 2012;22(6):765–80.23238013 10.1016/j.ccr.2012.11.005
15. Fan J Wei Q Koay EJ Liu Y Ning B Bernard PW Chemoresistance Transmission via exosome-mediated EphA2 transfer in pancreatic Cancer Theranostics 2018 8 21 5986 94 10.7150/thno.26650 30613276
Fan J, Wei Q, Koay EJ, Liu Y, Ning B, Bernard PW, et al. Chemoresistance Transmission via exosome-mediated EphA2 transfer in pancreatic Cancer. Theranostics. 2018;8(21):5986–94.30613276 10.7150/thno.26650
16. Garcia-Monclús S López-Alemany R Almacellas-Rabaiget O Herrero-Martín D Huertas-Martinez J Lagares-Tena L EphA2 receptor is a key player in the metastatic onset of ewing sarcoma Int J Cancer 2018 143 5 1188 201 10.1002/ijc.31405 29582409
Garcia-Monclús S, López-Alemany R, Almacellas-Rabaiget O, Herrero-Martín D, Huertas-Martinez J, Lagares-Tena L, et al. EphA2 receptor is a key player in the metastatic onset of ewing sarcoma. Int J Cancer. 2018;143(5):1188–201.29582409 10.1002/ijc.31405
17. Xiao T Xiao Y Wang W Tang YY Xiao Z Su M Targeting EphA2 in cancer J Hematol Oncol 2020 13 1 114 10.1186/s13045-020-00944-9 32811512
Xiao T, Xiao Y, Wang W, Tang YY, Xiao Z, Su M. Targeting EphA2 in cancer. J Hematol Oncol. 2020;13(1):114.32811512 10.1186/s13045-020-00944-9
18. Limited B. Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression [ https://clinicaltrials.gov/study/NCT04180371?term=epha2&rank=5&tab=table
19. Hospital CPG. Combination of CAR-DC Vaccine and ICIs in Malignant Tumors [ https://clinicaltrials.gov/study/NCT05631886?term=epha2&rank=3
20. Center MDAC. EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors [ https://clinicaltrials.gov/study/NCT01591356?term=epha2&rank=1
21. Wilson K Shiuan E Brantley-Sieders DM Oncogenic functions and therapeutic targeting of EphA2 in cancer Oncogene 2021 40 14 2483 95 10.1038/s41388-021-01714-8 33686241
Wilson K, Shiuan E, Brantley-Sieders DM. Oncogenic functions and therapeutic targeting of EphA2 in cancer. Oncogene. 2021;40(14):2483–95.33686241 10.1038/s41388-021-01714-8
22. Kania A Klein R Mechanisms of ephrin-eph signalling in development, physiology and disease Nat Rev Mol Cell Biol 2016 17 4 240 56 10.1038/nrm.2015.16 26790531
Kania A, Klein R. Mechanisms of ephrin-eph signalling in development, physiology and disease. Nat Rev Mol Cell Biol. 2016;17(4):240–56.26790531 10.1038/nrm.2015.16
23. Atlas THP. Eph receptors [ https://www.proteinatlas.org/search/eph+receptors
24. Lisabeth EM, Falivelli G, Pasquale EB. Eph receptor signaling and ephrins. Cold Spring Harb Perspect Biol. 2013;5(9).
25. Liang LY Patel O Janes PW Murphy JM Lucet IS Eph receptor signalling: from catalytic to non-catalytic functions Oncogene 2019 38 39 6567 84 10.1038/s41388-019-0931-2 31406248
Liang LY, Patel O, Janes PW, Murphy JM, Lucet IS. Eph receptor signalling: from catalytic to non-catalytic functions. Oncogene. 2019;38(39):6567–84.31406248 10.1038/s41388-019-0931-2
26. Pasquale EB Eph-ephrin promiscuity is now crystal clear Nat Neurosci 2004 7 5 417 8 10.1038/nn0504-417 15114347
Pasquale EB. Eph-ephrin promiscuity is now crystal clear. Nat Neurosci. 2004;7(5):417–8.15114347 10.1038/nn0504-417
27. Murai KK Pasquale EB Eph’ective signaling: forward, reverse and crosstalk J Cell Sci 2003 116 Pt 14 2823 32 10.1242/jcs.00625 12808016
Murai KK, Pasquale EB. Eph’ective signaling: forward, reverse and crosstalk. J Cell Sci. 2003;116(Pt 14):2823–32.12808016 10.1242/jcs.00625
28. Pasquale EB Eph receptors and ephrins in cancer: bidirectional signalling and beyond Nat Rev Cancer 2010 10 3 165 80 10.1038/nrc2806 20179713
Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer. 2010;10(3):165–80.20179713 10.1038/nrc2806
29. Pasquale EB Eph receptors and ephrins in cancer progression Nat Rev Cancer 2024 24 1 5 27 10.1038/s41568-023-00634-x 37996538
Pasquale EB. Eph receptors and ephrins in cancer progression. Nat Rev Cancer. 2024;24(1):5–27.37996538 10.1038/s41568-023-00634-x
30. Gatto G Morales D Kania A Klein R EphA4 receptor shedding regulates spinal motor axon guidance Curr Biol 2014 24 20 2355 65 10.1016/j.cub.2014.08.028 25264256
Gatto G, Morales D, Kania A, Klein R. EphA4 receptor shedding regulates spinal motor axon guidance. Curr Biol. 2014;24(20):2355–65.25264256 10.1016/j.cub.2014.08.028
31. Janes PW Wimmer-Kleikamp SH Frangakis AS Treble K Griesshaber B Sabet O Cytoplasmic relaxation of active eph controls ephrin shedding by ADAM10 PLoS Biol 2009 7 10 e1000215 10.1371/journal.pbio.1000215 19823572
Janes PW, Wimmer-Kleikamp SH, Frangakis AS, Treble K, Griesshaber B, Sabet O, et al. Cytoplasmic relaxation of active eph controls ephrin shedding by ADAM10. PLoS Biol. 2009;7(10):e1000215.19823572 10.1371/journal.pbio.1000215
32. Barquilla A Pasquale EB Eph receptors and ephrins: therapeutic opportunities Annu Rev Pharmacol Toxicol 2015 55 465 87 10.1146/annurev-pharmtox-011112-140226 25292427
Barquilla A, Pasquale EB. Eph receptors and ephrins: therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2015;55:465–87.25292427 10.1146/annurev-pharmtox-011112-140226
33. Ieguchi K Tomita T Omori T Komatsu A Deguchi A Masuda J ADAM12-cleaved ephrin-A1 contributes to lung metastasis Oncogene 2014 33 17 2179 90 10.1038/onc.2013.180 23686306
Ieguchi K, Tomita T, Omori T, Komatsu A, Deguchi A, Masuda J, et al. ADAM12-cleaved ephrin-A1 contributes to lung metastasis. Oncogene. 2014;33(17):2179–90.23686306 10.1038/onc.2013.180
34. Alford SC Bazowski J Lorimer H Elowe S Howard PL Tissue transglutaminase clusters soluble A-type ephrins into functionally active high molecular weight oligomers Exp Cell Res 2007 313 20 4170 9 10.1016/j.yexcr.2007.07.019 17707797
Alford SC, Bazowski J, Lorimer H, Elowe S, Howard PL. Tissue transglutaminase clusters soluble A-type ephrins into functionally active high molecular weight oligomers. Exp Cell Res. 2007;313(20):4170–9.17707797 10.1016/j.yexcr.2007.07.019
35. Lagares D Ghassemi-Kakroodi P Tremblay C Santos A Probst CK Franklin A ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis Nat Med 2017 23 12 1405 15 10.1038/nm.4419 29058717
Lagares D, Ghassemi-Kakroodi P, Tremblay C, Santos A, Probst CK, Franklin A, et al. ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis. Nat Med. 2017;23(12):1405–15.29058717 10.1038/nm.4419
36. EMBL-EBI Er -M, Gene. EPHA2 ENSG00000142627 2024 [ https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000142627;r=1:16126401-16158135
37. Park JE Son AI Zhou R Roles of EphA2 in Development and Disease Genes (Basel) 2013 4 3 334 57 10.3390/genes4030334 24705208
Park JE, Son AI, Zhou R. Roles of EphA2 in Development and Disease. Genes (Basel). 2013;4(3):334–57.24705208 10.3390/genes4030334
38. Hafner C Schmitz G Meyer S Bataille F Hau P Langmann T Differential gene expression of eph receptors and ephrins in benign human tissues and cancers Clin Chem 2004 50 3 490 9 10.1373/clinchem.2003.026849 14726470
Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, et al. Differential gene expression of eph receptors and ephrins in benign human tissues and cancers. Clin Chem. 2004;50(3):490–9.14726470 10.1373/clinchem.2003.026849
39. Ieguchi K Maru Y Roles of EphA1/A2 and ephrin-A1 in cancer Cancer Sci 2019 110 3 841 8 10.1111/cas.13942 30657619
Ieguchi K, Maru Y. Roles of EphA1/A2 and ephrin-A1 in cancer. Cancer Sci. 2019;110(3):841–8.30657619 10.1111/cas.13942
40. Noberini R de la Rubio E Pasquale EB Profiling eph receptor expression in cells and tissues: a targeted mass spectrometry approach Cell Adh Migr 2012 6 2 102 12 10.4161/cam.19620 22568954
Noberini R, de la Rubio E, Pasquale EB. Profiling eph receptor expression in cells and tissues: a targeted mass spectrometry approach. Cell Adh Migr. 2012;6(2):102–12.22568954 10.4161/cam.19620
41. Himanen JP Goldgur Y Miao H Myshkin E Guo H Buck M Ligand recognition by A-class eph receptors: crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex EMBO Rep 2009 10 7 722 8 10.1038/embor.2009.91 19525919
Himanen JP, Goldgur Y, Miao H, Myshkin E, Guo H, Buck M, et al. Ligand recognition by A-class eph receptors: crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex. EMBO Rep. 2009;10(7):722–8.19525919 10.1038/embor.2009.91
42. Zhou Y Sakurai H Emerging and diverse functions of the EphA2 noncanonical pathway in Cancer Progression Biol Pharm Bull 2017 40 10 1616 24 10.1248/bpb.b17-00446 28966234
Zhou Y, Sakurai H. Emerging and diverse functions of the EphA2 noncanonical pathway in Cancer Progression. Biol Pharm Bull. 2017;40(10):1616–24.28966234 10.1248/bpb.b17-00446
43. Tandon M Vemula SV Mittal SK Emerging strategies for EphA2 receptor targeting for cancer therapeutics Expert Opin Ther Targets 2011 15 1 31 51 10.1517/14728222.2011.538682 21142802
Tandon M, Vemula SV, Mittal SK. Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets. 2011;15(1):31–51.21142802 10.1517/14728222.2011.538682
44. Ireton RC Chen J EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics Curr Cancer Drug Targets 2005 5 3 149 57 10.2174/1568009053765780 15892616
Ireton RC, Chen J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets. 2005;5(3):149–57.15892616 10.2174/1568009053765780
45. Kim J Chang IY You HJ Interactions between EGFR and EphA2 promote tumorigenesis through the action of Ephexin1 Cell Death Dis 2022 13 6 528 10.1038/s41419-022-04984-6 35668076
Kim J, Chang IY, You HJ. Interactions between EGFR and EphA2 promote tumorigenesis through the action of Ephexin1. Cell Death Dis. 2022;13(6):528.35668076 10.1038/s41419-022-04984-6
46. Brantley-Sieders DM Zhuang G Hicks D Fang WB Hwang Y Cates JM The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling J Clin Invest 2008 118 1 64 78 10.1172/JCI33154 18079969
Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest. 2008;118(1):64–78.18079969 10.1172/JCI33154
47. Paul MD Grubb HN Hristova K Quantifying the strength of heterointeractions among receptor tyrosine kinases from different subfamilies: implications for cell signaling J Biol Chem 2020 295 29 9917 33 10.1074/jbc.RA120.013639 32467228
Paul MD, Grubb HN, Hristova K. Quantifying the strength of heterointeractions among receptor tyrosine kinases from different subfamilies: implications for cell signaling. J Biol Chem. 2020;295(29):9917–33.32467228 10.1074/jbc.RA120.013639
48. Zantek ND Azimi M Fedor-Chaiken M Wang B Brackenbury R Kinch MS E-cadherin regulates the function of the EphA2 receptor tyrosine kinase Cell Growth Differ 1999 10 9 629 38 10511313
Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R, Kinch MS. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ. 1999;10(9):629–38.10511313
49. Gai QJ Fu Z He J Mao M Yao XX Qin Y EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma Signal Transduct Target Ther 2022 7 1 33 10.1038/s41392-021-00855-2 35105853
Gai QJ, Fu Z, He J, Mao M, Yao XX, Qin Y, et al. EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma. Signal Transduct Target Ther. 2022;7(1):33.35105853 10.1038/s41392-021-00855-2
50. Hamaoka Y Negishi M Katoh H EphA2 is a key effector of the MEK/ERK/RSK pathway regulating glioblastoma cell proliferation Cell Signal 2016 28 8 937 45 10.1016/j.cellsig.2016.04.009 27132626
Hamaoka Y, Negishi M, Katoh H. EphA2 is a key effector of the MEK/ERK/RSK pathway regulating glioblastoma cell proliferation. Cell Signal. 2016;28(8):937–45.27132626 10.1016/j.cellsig.2016.04.009
51. Barquilla A Lamberto I Noberini R Heynen-Genel S Brill LM Pasquale EB Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation Mol Biol Cell 2016 27 17 2757 70 10.1091/mbc.e16-01-0048 27385333
Barquilla A, Lamberto I, Noberini R, Heynen-Genel S, Brill LM, Pasquale EB. Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation. Mol Biol Cell. 2016;27(17):2757–70.27385333 10.1091/mbc.e16-01-0048
52. Gehring MP Pasquale EB Protein kinase C phosphorylates the EphA2 receptor on serine 892 in the regulatory linker connecting the kinase and SAM domains Cell Signal 2020 73 109668 10.1016/j.cellsig.2020.109668 32413552
Gehring MP, Pasquale EB. Protein kinase C phosphorylates the EphA2 receptor on serine 892 in the regulatory linker connecting the kinase and SAM domains. Cell Signal. 2020;73:109668.32413552 10.1016/j.cellsig.2020.109668
53. Kawai H Kobayashi M Hiramoto-Yamaki N Harada K Negishi M Katoh H Ephexin4-mediated promotion of cell migration and anoikis resistance is regulated by serine 897 phosphorylation of EphA2 FEBS Open Bio 2013 3 78 82 10.1016/j.fob.2013.01.002 23772378
Kawai H, Kobayashi M, Hiramoto-Yamaki N, Harada K, Negishi M, Katoh H. Ephexin4-mediated promotion of cell migration and anoikis resistance is regulated by serine 897 phosphorylation of EphA2. FEBS Open Bio. 2013;3:78–82.23772378 10.1016/j.fob.2013.01.002
54. Harada K Hiramoto-Yamaki N Negishi M Katoh H Ephexin4 and EphA2 mediate resistance to anoikis through RhoG and phosphatidylinositol 3-kinase Exp Cell Res 2011 317 12 1701 13 10.1016/j.yexcr.2011.05.014 21621533
Harada K, Hiramoto-Yamaki N, Negishi M, Katoh H. Ephexin4 and EphA2 mediate resistance to anoikis through RhoG and phosphatidylinositol 3-kinase. Exp Cell Res. 2011;317(12):1701–13.21621533 10.1016/j.yexcr.2011.05.014
55. Beauchamp A Debinski W Ephs and ephrins in cancer: ephrin-A1 signalling Semin Cell Dev Biol 2012 23 1 109 15 10.1016/j.semcdb.2011.10.019 22040911
Beauchamp A, Debinski W. Ephs and ephrins in cancer: ephrin-A1 signalling. Semin Cell Dev Biol. 2012;23(1):109–15.22040911 10.1016/j.semcdb.2011.10.019
56. Miao H Burnett E Kinch M Simon E Wang B Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation Nat Cell Biol 2000 2 2 62 9 10.1038/35000008 10655584
Miao H, Burnett E, Kinch M, Simon E, Wang B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol. 2000;2(2):62–9.10655584 10.1038/35000008
57. Kikawa KD Vidale DR Van Etten RL Kinch MS Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation J Biol Chem 2002 277 42 39274 9 10.1074/jbc.M207127200 12167657
Kikawa KD, Vidale DR, Van Etten RL, Kinch MS. Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J Biol Chem. 2002;277(42):39274–9.12167657 10.1074/jbc.M207127200
58. Fang WB Ireton RC Zhuang G Takahashi T Reynolds A Chen J Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism J Cell Sci 2008 121 Pt 3 358 68 10.1242/jcs.017145 18198190
Fang WB, Ireton RC, Zhuang G, Takahashi T, Reynolds A, Chen J. Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism. J Cell Sci. 2008;121(Pt 3):358–68.18198190 10.1242/jcs.017145
59. Udayakumar D Zhang G Ji Z Njauw CN Mroz P Tsao H EphA2 is a critical oncogene in melanoma Oncogene 2011 30 50 4921 9 10.1038/onc.2011.210 21666714
Udayakumar D, Zhang G, Ji Z, Njauw CN, Mroz P, Tsao H. EphA2 is a critical oncogene in melanoma. Oncogene. 2011;30(50):4921–9.21666714 10.1038/onc.2011.210
60. Parri M Taddei ML Bianchini F Calorini L Chiarugi P EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style Cancer Res 2009 69 5 2072 81 10.1158/0008-5472.CAN-08-1845 19244130
Parri M, Taddei ML, Bianchini F, Calorini L, Chiarugi P. EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. Cancer Res. 2009;69(5):2072–81.19244130 10.1158/0008-5472.CAN-08-1845
61. Mo J Zhao X Dong X Liu T Zhao N Zhang D Effect of EphA2 knockdown on melanoma metastasis depends on intrinsic ephrinA1 level Cell Oncol (Dordr) 2020 43 4 655 67 10.1007/s13402-020-00511-x 32291572
Mo J, Zhao X, Dong X, Liu T, Zhao N, Zhang D, et al. Effect of EphA2 knockdown on melanoma metastasis depends on intrinsic ephrinA1 level. Cell Oncol (Dordr). 2020;43(4):655–67.32291572 10.1007/s13402-020-00511-x
62. Fritsche-Guenther R Noske A Ungethüm U Kuban RJ Schlag PM Tunn PU De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway Histopathology 2010 57 6 836 50 10.1111/j.1365-2559.2010.03713.x 21166698
Fritsche-Guenther R, Noske A, Ungethüm U, Kuban RJ, Schlag PM, Tunn PU, et al. De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway. Histopathology. 2010;57(6):836–50.21166698 10.1111/j.1365-2559.2010.03713.x
63. Wykosky J Gibo DM Stanton C Debinski W EphA2 as a novel molecular marker and target in glioblastoma multiforme Mol Cancer Res 2005 3 10 541 51 10.1158/1541-7786.MCR-05-0056 16254188
Wykosky J, Gibo DM, Stanton C, Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res. 2005;3(10):541–51.16254188 10.1158/1541-7786.MCR-05-0056
64. Liu F Park PJ Lai W Maher E Chakravarti A Durso L A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma Cancer Res 2006 66 22 10815 23 10.1158/0008-5472.CAN-06-1408 17090523
Liu F, Park PJ, Lai W, Maher E, Chakravarti A, Durso L, et al. A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Res. 2006;66(22):10815–23.17090523 10.1158/0008-5472.CAN-06-1408
65. Kinch MS Moore MB Harpole DH Jr. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival Clin Cancer Res 2003 9 2 613 8 12576426
Kinch MS, Moore MB, Harpole DH. Jr. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res. 2003;9(2):613–8.12576426
66. Martini G Cardone C Vitiello PP Belli V Napolitano S Troiani T EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving Antiepidermal Growth factor receptor therapy in Colorectal Cancer Mol Cancer Ther 2019 18 4 845 55 10.1158/1535-7163.MCT-18-0539 30824612
Martini G, Cardone C, Vitiello PP, Belli V, Napolitano S, Troiani T, et al. EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving Antiepidermal Growth factor receptor therapy in Colorectal Cancer. Mol Cancer Ther. 2019;18(4):845–55.30824612 10.1158/1535-7163.MCT-18-0539
67. Walker-Daniels J Coffman K Azimi M Rhim JS Bostwick DG Snyder P Overexpression of the EphA2 tyrosine kinase in prostate cancer Prostate 1999 41 4 275 80 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T 10544301
Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, et al. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate. 1999;41(4):275–80.10544301 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T
68. Mudali SV Fu B Lakkur SS Luo M Embuscado EE Iacobuzio-Donahue CA Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status Clin Exp Metastasis 2006 23 7–8 357 65 17146615
Mudali SV, Fu B, Lakkur SS, Luo M, Embuscado EE, Iacobuzio-Donahue CA. Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. Clin Exp Metastasis. 2006;23(7–8):357–65.17146615
69. Wu D Suo Z Kristensen GB Li S Troen G Holm R Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma Gynecol Oncol 2004 94 2 312 9 10.1016/j.ygyno.2004.05.019 15297167
Wu D, Suo Z, Kristensen GB, Li S, Troen G, Holm R, et al. Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma. Gynecol Oncol. 2004;94(2):312–9.15297167 10.1016/j.ygyno.2004.05.019
70. Brannan JM Sen B Saigal B Prudkin L Behrens C Solis L EphA2 in the early pathogenesis and progression of non-small cell lung cancer Cancer Prev Res (Phila) 2009 2 12 1039 49 10.1158/1940-6207.CAPR-09-0212 19934338
Brannan JM, Sen B, Saigal B, Prudkin L, Behrens C, Solis L, et al. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila). 2009;2(12):1039–49.19934338 10.1158/1940-6207.CAPR-09-0212
71. Zelinski DP Zantek ND Stewart JC Irizarry AR Kinch MS EphA2 overexpression causes tumorigenesis of mammary epithelial cells Cancer Res 2001 61 5 2301 6 11280802
Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res. 2001;61(5):2301–6.11280802
72. Nakamura R Kataoka H Sato N Kanamori M Ihara M Igarashi H EPHA2/EFNA1 expression in human gastric cancer Cancer Sci 2005 96 1 42 7 10.1111/j.1349-7006.2005.00007.x 15649254
Nakamura R, Kataoka H, Sato N, Kanamori M, Ihara M, Igarashi H, et al. EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci. 2005;96(1):42–7.15649254 10.1111/j.1349-7006.2005.00007.x
73. Fang WB Brantley-Sieders DM Parker MA Reith AD Chen J A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis Oncogene 2005 24 53 7859 68 10.1038/sj.onc.1208937 16103880
Fang WB, Brantley-Sieders DM, Parker MA, Reith AD, Chen J. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene. 2005;24(53):7859–68.16103880 10.1038/sj.onc.1208937
74. Dunne PD Dasgupta S Blayney JK McArt DG Redmond KL Weir JA EphA2 expression is a key driver of Migration and Invasion and a poor prognostic marker in Colorectal Cancer Clin Cancer Res 2016 22 1 230 42 10.1158/1078-0432.CCR-15-0603 26283684
Dunne PD, Dasgupta S, Blayney JK, McArt DG, Redmond KL, Weir JA, et al. EphA2 expression is a key driver of Migration and Invasion and a poor prognostic marker in Colorectal Cancer. Clin Cancer Res. 2016;22(1):230–42.26283684 10.1158/1078-0432.CCR-15-0603
75. Kurose H Ueda K Kondo R Ogasawara S Kusano H Sanada S Elevated expression of EPHA2 is Associated with Poor Prognosis after radical prostatectomy in prostate Cancer Anticancer Res 2019 39 11 6249 57 10.21873/anticanres.13834 31704854
Kurose H, Ueda K, Kondo R, Ogasawara S, Kusano H, Sanada S, et al. Elevated expression of EPHA2 is Associated with Poor Prognosis after radical prostatectomy in prostate Cancer. Anticancer Res. 2019;39(11):6249–57.31704854 10.21873/anticanres.13834
76. Kamat AA Coffey D Merritt WM Nugent E Urbauer D Lin YG EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer Cancer 2009 115 12 2684 92 10.1002/cncr.24335 19396818
Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin YG, et al. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer. 2009;115(12):2684–92.19396818 10.1002/cncr.24335
77. Miyazaki T Kato H Fukuchi M Nakajima M Kuwano H EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma Int J Cancer 2003 103 5 657 63 10.1002/ijc.10860 12494475
Miyazaki T, Kato H, Fukuchi M, Nakajima M, Kuwano H. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer. 2003;103(5):657–63.12494475 10.1002/ijc.10860
78. Takasugi M Okada R Takahashi A Virya Chen D Watanabe S Hara E Small extracellular vesicles secreted from senescent cells promote cancer cell proliferation through EphA2 Nat Commun 2017 8 15729 10.1038/ncomms15728 28585531
Takasugi M, Okada R, Takahashi A, Virya Chen D, Watanabe S, Hara E. Small extracellular vesicles secreted from senescent cells promote cancer cell proliferation through EphA2. Nat Commun. 2017;8:15729.28585531 10.1038/ncomms15728
79. Wei Q Wei L Zhang J Li Z Feng H Ren L EphA2–enriched exosomes promote cell migration and are a potential diagnostic serum marker in pancreatic cancer Mol Med Rep 2020 22 4 2941 7 32945400
Wei Q, Wei L, Zhang J, Li Z, Feng H, Ren L. EphA2–enriched exosomes promote cell migration and are a potential diagnostic serum marker in pancreatic cancer. Mol Med Rep. 2020;22(4):2941–7.32945400
80. Yamashita T Kamada H Kanasaki S Nagano K Inoue M Higashisaka K Ephrin type-A receptor 2 on tumor-derived exosomes enhances angiogenesis through the activation of MAPK signaling Pharmazie 2019 74 10 614 9 31685088
Yamashita T, Kamada H, Kanasaki S, Nagano K, Inoue M, Higashisaka K, et al. Ephrin type-A receptor 2 on tumor-derived exosomes enhances angiogenesis through the activation of MAPK signaling. Pharmazie. 2019;74(10):614–9.31685088
81. Liu X Li Y Chen C Dong J Zhou J Tong D Exosomal EphA2 promotes tumor metastasis of triple-negative breast cancer by damaging endothelial barrier Clin Exp Metastasis 2023 40 1 105 16 10.1007/s10585-022-10194-3 36380015
Liu X, Li Y, Chen C, Dong J, Zhou J, Tong D, et al. Exosomal EphA2 promotes tumor metastasis of triple-negative breast cancer by damaging endothelial barrier. Clin Exp Metastasis. 2023;40(1):105–16.36380015 10.1007/s10585-022-10194-3
82. Hong HN Won YJ Shim JH Kim HJ Han SH Kim BS Cancer-associated fibroblasts promote gastric tumorigenesis through EphA2 activation in a ligand-independent manner J Cancer Res Clin Oncol 2018 144 9 1649 63 10.1007/s00432-018-2683-8 29948146
Hong HN, Won YJ, Shim JH, Kim HJ, Han SH, Kim BS, et al. Cancer-associated fibroblasts promote gastric tumorigenesis through EphA2 activation in a ligand-independent manner. J Cancer Res Clin Oncol. 2018;144(9):1649–63.29948146 10.1007/s00432-018-2683-8
83. Kim HS Won YJ Shim JH Kim HJ Kim BS Hong HN Role of EphA2-PI3K signaling in vasculogenic mimicry induced by cancer-associated fibroblasts in gastric cancer cells Oncol Lett 2019 18 3 3031 8 31452781
Kim HS, Won YJ, Shim JH, Kim HJ, Kim BS, Hong HN. Role of EphA2-PI3K signaling in vasculogenic mimicry induced by cancer-associated fibroblasts in gastric cancer cells. Oncol Lett. 2019;18(3):3031–8.31452781
84. Sáinz-Jaspeado M Huertas-Martinez J Lagares-Tena L Martin Liberal J Mateo-Lozano S de Alava E EphA2-induced angiogenesis in ewing sarcoma cells works through bFGF production and is dependent on caveolin-1 PLoS ONE 2013 8 8 e71449 10.1371/journal.pone.0071449 23951165
Sáinz-Jaspeado M, Huertas-Martinez J, Lagares-Tena L, Martin Liberal J, Mateo-Lozano S, de Alava E, et al. EphA2-induced angiogenesis in ewing sarcoma cells works through bFGF production and is dependent on caveolin-1. PLoS ONE. 2013;8(8):e71449.23951165 10.1371/journal.pone.0071449
85. Hadjimichael AC, Pergaris A, Kaspiris A, Foukas AF, Kokkali S, Tsourouflis G et al. The EPH/Ephrin System in Bone and Soft Tissue Sarcomas’ Pathogenesis and Therapy: New Advancements and a Literature Review. Int J Mol Sci. 2022;23(9).
86. Mirabello L Troisi RJ Savage SA Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and end results program Cancer 2009 115 7 1531 43 10.1002/cncr.24121 19197972
Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and end results program. Cancer. 2009;115(7):1531–43.19197972 10.1002/cncr.24121
87. Zhao X Wu Q Gong X Liu J Ma Y Osteosarcoma: a review of current and future therapeutic approaches Biomed Eng Online 2021 20 1 24 10.1186/s12938-021-00860-0 33653371
Zhao X, Wu Q, Gong X, Liu J, Ma Y. Osteosarcoma: a review of current and future therapeutic approaches. Biomed Eng Online. 2021;20(1):24.33653371 10.1186/s12938-021-00860-0
88. Brown HK Schiavone K Gouin F Heymann MF Heymann D Biology of Bone Sarcomas and New Therapeutic developments Calcif Tissue Int 2018 102 2 174 95 10.1007/s00223-017-0372-2 29238848
Brown HK, Schiavone K, Gouin F, Heymann MF, Heymann D. Biology of Bone Sarcomas and New Therapeutic developments. Calcif Tissue Int. 2018;102(2):174–95.29238848 10.1007/s00223-017-0372-2
89. Rothzerg E Xu J Wood D Different subtypes of Osteosarcoma: histopathological patterns and clinical Behaviour J Mol Pathol 2023 4 2 99 108 10.3390/jmp4020011
Rothzerg E, Xu J, Wood D. Different subtypes of Osteosarcoma: histopathological patterns and clinical Behaviour. J Mol Pathol. 2023;4(2):99–108.10.3390/jmp4020011
90. Martin JW Squire JA Zielenska M The genetics of osteosarcoma Sarcoma 2012 2012 627254 10.1155/2012/627254 22685381
Martin JW, Squire JA, Zielenska M. The genetics of osteosarcoma. Sarcoma. 2012;2012:627254.22685381 10.1155/2012/627254
91. Morrow JJ Khanna C Osteosarcoma Genetics and epigenetics: emerging Biology and candidate therapies Crit Rev Oncog 2015 20 3–4 173 97 10.1615/CritRevOncog.2015013713 26349415
Morrow JJ, Khanna C. Osteosarcoma Genetics and epigenetics: emerging Biology and candidate therapies. Crit Rev Oncog. 2015;20(3–4):173–97.26349415 10.1615/CritRevOncog.2015013713
92. Liu W Wang R Zhang Y Wang H Huang Z Jin T Whole-exome sequencing in osteosarcoma with distinct prognosis reveals disparate genetic heterogeneity Cancer Genet 2021 256–257 149 57 10.1016/j.cancergen.2021.05.013 34153775
Liu W, Wang R, Zhang Y, Wang H, Huang Z, Jin T, et al. Whole-exome sequencing in osteosarcoma with distinct prognosis reveals disparate genetic heterogeneity. Cancer Genet. 2021;256–257:149–57.34153775 10.1016/j.cancergen.2021.05.013
93. Pastorino U Palmerini E Porcu L Luksch R Scanagatta P Meazza C Lung metastasectomy for osteosarcoma in children, adolescents, and young adults: proof of permanent cure Tumori 2023 109 1 79 85 10.1177/03008916211053048 34674575
Pastorino U, Palmerini E, Porcu L, Luksch R, Scanagatta P, Meazza C, et al. Lung metastasectomy for osteosarcoma in children, adolescents, and young adults: proof of permanent cure. Tumori. 2023;109(1):79–85.34674575 10.1177/03008916211053048
94. Smeland S Bielack SS Whelan J Bernstein M Hogendoorn P Krailo MD Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort Eur J Cancer 2019 109 36 50 10.1016/j.ejca.2018.11.027 30685685
Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019;109:36–50.30685685 10.1016/j.ejca.2018.11.027
95. Posthumadeboer J Piersma SR Pham TV van Egmond PW Knol JC Cleton-Jansen AM Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery Br J Cancer 2013 109 8 2142 54 10.1038/bjc.2013.578 24064975
Posthumadeboer J, Piersma SR, Pham TV, van Egmond PW, Knol JC, Cleton-Jansen AM, et al. Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery. Br J Cancer. 2013;109(8):2142–54.24064975 10.1038/bjc.2013.578
96. Cole S Gianferante DM Zhu B Mirabello L Osteosarcoma A surveillance, epidemiology, and end results program-based analysis from 1975 to 2017 Cancer 2022 128 11 2107 18 10.1002/cncr.34163 35226758
Cole S, Gianferante DM, Zhu B, Mirabello L, Osteosarcoma. A surveillance, epidemiology, and end results program-based analysis from 1975 to 2017. Cancer. 2022;128(11):2107–18.35226758 10.1002/cncr.34163
97. Williams RF Fernandez-Pineda I Gosain A Pediatric Sarcomas Surg Clin North Am 2016 96 5 1107 25 10.1016/j.suc.2016.05.012 27542645
Williams RF, Fernandez-Pineda I, Gosain A. Pediatric Sarcomas. Surg Clin North Am. 2016;96(5):1107–25.27542645 10.1016/j.suc.2016.05.012
98. Bühnemann C Li S Yu H Branford White H Schäfer KL Llombart-Bosch A Quantification of the heterogeneity of prognostic cellular biomarkers in ewing sarcoma using automated image and random survival forest analysis PLoS ONE 2014 9 9 e107105 10.1371/journal.pone.0107105 25243408
Bühnemann C, Li S, Yu H, Branford White H, Schäfer KL, Llombart-Bosch A, et al. Quantification of the heterogeneity of prognostic cellular biomarkers in ewing sarcoma using automated image and random survival forest analysis. PLoS ONE. 2014;9(9):e107105.25243408 10.1371/journal.pone.0107105
99. Zhang N Liu H Yue G Zhang Y You J Wang H Molecular Heterogeneity of Ewing Sarcoma as detected by Ion Torrent sequencing PLoS ONE 2016 11 4 e0153546 10.1371/journal.pone.0153546 27077911
Zhang N, Liu H, Yue G, Zhang Y, You J, Wang H. Molecular Heterogeneity of Ewing Sarcoma as detected by Ion Torrent sequencing. PLoS ONE. 2016;11(4):e0153546.27077911 10.1371/journal.pone.0153546
100. Brohl AS Solomon DA Chang W Wang J Song Y Sindiri S The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation PLoS Genet 2014 10 7 e1004475 10.1371/journal.pgen.1004475 25010205
Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, et al. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet. 2014;10(7):e1004475.25010205 10.1371/journal.pgen.1004475
101. Zöllner SK, Amatruda JF, Bauer S, Collaud S, de Álava E, DuBois SG et al. Ewing Sarcoma-Diagnosis, treatment, Clinical challenges and Future perspectives. J Clin Med. 2021;10(8).
102. Franzetti GA Laud-Duval K van der Ent W Brisac A Irondelle M Aubert S Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in ewing sarcoma cells Oncogene 2017 36 25 3505 14 10.1038/onc.2016.498 28135250
Franzetti GA, Laud-Duval K, van der Ent W, Brisac A, Irondelle M, Aubert S, et al. Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in ewing sarcoma cells. Oncogene. 2017;36(25):3505–14.28135250 10.1038/onc.2016.498
103. Meyers PA, Federman N, Daw N, Anderson PM, Davis LE, Kim A et al. Open-Label, Multicenter, Phase I/II, First-in-human trial of TK216: a First-Generation EWS::FLI1 Fusion protein antagonist in Ewing Sarcoma. J Clin Oncol. 2024:Jco2400020.
104. Zhang ZB Cai L Zheng SG Xiong Y Dong JH Overexpression of caveolin-1 in hepatocellular carcinoma with metastasis and worse prognosis: correlation with vascular endothelial growth factor, microvessel density and unpaired artery Pathol Oncol Res 2009 15 3 495 502 10.1007/s12253-008-9144-7 19434519
Zhang ZB, Cai L, Zheng SG, Xiong Y, Dong JH. Overexpression of caveolin-1 in hepatocellular carcinoma with metastasis and worse prognosis: correlation with vascular endothelial growth factor, microvessel density and unpaired artery. Pathol Oncol Res. 2009;15(3):495–502.19434519 10.1007/s12253-008-9144-7
105. Yang G Addai J Wheeler TM Frolov A Miles BJ Kadmon D Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis Hum Pathol 2007 38 11 1688 95 10.1016/j.humpath.2007.03.024 17707459
Yang G, Addai J, Wheeler TM, Frolov A, Miles BJ, Kadmon D, et al. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol. 2007;38(11):1688–95.17707459 10.1016/j.humpath.2007.03.024
106. Sáinz-Jaspeado M Lagares-Tena L Lasheras J Navid F Rodriguez-Galindo C Mateo-Lozano S Caveolin-1 modulates the ability of Ewing’s sarcoma to metastasize Mol Cancer Res 2010 8 11 1489 500 10.1158/1541-7786.MCR-10-0060 21106507
Sáinz-Jaspeado M, Lagares-Tena L, Lasheras J, Navid F, Rodriguez-Galindo C, Mateo-Lozano S, et al. Caveolin-1 modulates the ability of Ewing’s sarcoma to metastasize. Mol Cancer Res. 2010;8(11):1489–500.21106507 10.1158/1541-7786.MCR-10-0060
107. Jin W The role of Tyrosine Kinases as a critical prognostic parameter and its targeted therapies in Ewing Sarcoma Front Cell Dev Biol 2020 8 613 10.3389/fcell.2020.00613 32754598
Jin W. The role of Tyrosine Kinases as a critical prognostic parameter and its targeted therapies in Ewing Sarcoma. Front Cell Dev Biol. 2020;8:613.32754598 10.3389/fcell.2020.00613
108. Duchman KR Gao Y Miller BJ Prognostic factors for survival in patients with Ewing’s sarcoma using the surveillance, epidemiology, and end results (SEER) program database Cancer Epidemiol 2015 39 2 189 95 10.1016/j.canep.2014.12.012 25595632
Duchman KR, Gao Y, Miller BJ. Prognostic factors for survival in patients with Ewing’s sarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol. 2015;39(2):189–95.25595632 10.1016/j.canep.2014.12.012
109. Jagodzinska-Mucha P, Raciborska A, Kosela-Paterczyk H, Kozak K, Bilska K, Switaj T et al. Age as a prognostic factor in patients with Ewing sarcoma-the Polish Sarcoma Group Experience. J Clin Med. 2021;10(16).
110. Sandberg AA Genetics of chondrosarcoma and related tumors Curr Opin Oncol 2004 16 4 342 54 10.1097/01.cco.0000129678.72521.e5 15187889
Sandberg AA. Genetics of chondrosarcoma and related tumors. Curr Opin Oncol. 2004;16(4):342–54.15187889 10.1097/01.cco.0000129678.72521.e5
111. Frezza AM Cesari M Baumhoer D Biau D Bielack S Campanacci DA Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study Eur J Cancer 2015 51 3 374 81 10.1016/j.ejca.2014.11.007 25529371
Frezza AM, Cesari M, Baumhoer D, Biau D, Bielack S, Campanacci DA, et al. Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. Eur J Cancer. 2015;51(3):374–81.25529371 10.1016/j.ejca.2014.11.007
112. Zhang YX van Oosterwijk JG Sicinska E Moss S Remillard SP van Wezel T Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy Clin Cancer Res 2013 19 14 3796 807 10.1158/1078-0432.CCR-12-3647 23714727
Zhang YX, van Oosterwijk JG, Sicinska E, Moss S, Remillard SP, van Wezel T, et al. Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy. Clin Cancer Res. 2013;19(14):3796–807.23714727 10.1158/1078-0432.CCR-12-3647
113. Amato KR Wang S Hastings AK Youngblood VM Santapuram PR Chen H Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC J Clin Invest 2014 124 5 2037 49 10.1172/JCI72522 24713656
Amato KR, Wang S, Hastings AK, Youngblood VM, Santapuram PR, Chen H, et al. Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC. J Clin Invest. 2014;124(5):2037–49.24713656 10.1172/JCI72522
114. Ishigaki H Minami T Morimura O Kitai H Horio D Koda Y EphA2 inhibition suppresses proliferation of small-cell lung cancer cells through inducing cell cycle arrest Biochem Biophys Res Commun 2019 519 4 846 53 10.1016/j.bbrc.2019.09.076 31558317
Ishigaki H, Minami T, Morimura O, Kitai H, Horio D, Koda Y, et al. EphA2 inhibition suppresses proliferation of small-cell lung cancer cells through inducing cell cycle arrest. Biochem Biophys Res Commun. 2019;519(4):846–53.31558317 10.1016/j.bbrc.2019.09.076
115. Zhang T Li J Ma X Yang Y Sun W Jin W Inhibition of HDACs-EphA2 Signaling Axis with WW437 demonstrates promising Preclinical Antitumor activity in breast Cancer EBioMedicine 2018 31 276 86 10.1016/j.ebiom.2018.05.003 29759486
Zhang T, Li J, Ma X, Yang Y, Sun W, Jin W, et al. Inhibition of HDACs-EphA2 Signaling Axis with WW437 demonstrates promising Preclinical Antitumor activity in breast Cancer. EBioMedicine. 2018;31:276–86.29759486 10.1016/j.ebiom.2018.05.003
116. Zhou Z Yuan X Li Z Tu H Li D Qing J RNA interference targeting EphA2 inhibits proliferation, induces apoptosis, and cooperates with cytotoxic drugs in human glioma cells Surg Neurol 2008 70 6 562 8 10.1016/j.surneu.2008.04.031 18614215
Zhou Z, Yuan X, Li Z, Tu H, Li D, Qing J, et al. RNA interference targeting EphA2 inhibits proliferation, induces apoptosis, and cooperates with cytotoxic drugs in human glioma cells. Surg Neurol. 2008;70(6):562–8. discussion 8–9.18614215 10.1016/j.surneu.2008.04.031
117. Corydon IJ Fabian-Jessing BK Jakobsen TS Jørgensen AC Jensen EG Askou AL 25 years of maturation: a systematic review of RNAi in the clinic Mol Ther Nucleic Acids 2023 33 469 82 10.1016/j.omtn.2023.07.018 37583575
Corydon IJ, Fabian-Jessing BK, Jakobsen TS, Jørgensen AC, Jensen EG, Askou AL, et al. 25 years of maturation: a systematic review of RNAi in the clinic. Mol Ther Nucleic Acids. 2023;33:469–82.37583575 10.1016/j.omtn.2023.07.018
118. Landen CN Jr Chavez-Reyes A Bucana C Schmandt R Deavers MT Lopez-Berestein G Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery Cancer Res 2005 65 15 6910 8 10.1158/0008-5472.CAN-05-0530 16061675
Landen CN Jr., Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005;65(15):6910–8.16061675 10.1158/0008-5472.CAN-05-0530
119. Wagner MJ Mitra R McArthur MJ Baze W Barnhart K Wu SY Preclinical mammalian Safety studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA) Mol Cancer Ther 2017 16 6 1114 23 10.1158/1535-7163.MCT-16-0541 28265009
Wagner MJ, Mitra R, McArthur MJ, Baze W, Barnhart K, Wu SY, et al. Preclinical mammalian Safety studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Mol Cancer Ther. 2017;16(6):1114–23.28265009 10.1158/1535-7163.MCT-16-0541
120. Choi KM Park GL Hwang KY Lee JW Ahn HJ Efficient siRNA delivery into tumor cells by p19-YSA fusion protein Mol Pharm 2013 10 2 763 73 10.1021/mp300344p 23276207
Choi KM, Park GL, Hwang KY, Lee JW, Ahn HJ. Efficient siRNA delivery into tumor cells by p19-YSA fusion protein. Mol Pharm. 2013;10(2):763–73.23276207 10.1021/mp300344p
121. Ozcan G Ozpolat B Coleman RL Sood AK Lopez-Berestein G Preclinical and clinical development of siRNA-based therapeutics Adv Drug Deliv Rev 2015 87 108 19 10.1016/j.addr.2015.01.007 25666164
Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015;87:108–19.25666164 10.1016/j.addr.2015.01.007
122. Oner E Kotmakci M Baird AM Gray SG Debelec Butuner B Bozkurt E Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids J Nanobiotechnol 2021 19 1 71 10.1186/s12951-021-00781-z
Oner E, Kotmakci M, Baird AM, Gray SG, Debelec Butuner B, Bozkurt E, et al. Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids. J Nanobiotechnol. 2021;19(1):71.10.1186/s12951-021-00781-z
123. Tsouko E Wang J Frigo DE Aydoğdu E Williams C miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene Carcinogenesis 2015 36 9 1051 60 10.1093/carcin/bgv087 26088362
Tsouko E, Wang J, Frigo DE, Aydoğdu E, Williams C. miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene. Carcinogenesis. 2015;36(9):1051–60.26088362 10.1093/carcin/bgv087
124. Li H Sun Q Han B Yu X Hu B Hu S MiR-26b inhibits hepatocellular carcinoma cell proliferation, migration, and invasion by targeting EphA2 Int J Clin Exp Pathol 2015 8 5 4782 90 26191168
Li H, Sun Q, Han B, Yu X, Hu B, Hu S. MiR-26b inhibits hepatocellular carcinoma cell proliferation, migration, and invasion by targeting EphA2. Int J Clin Exp Pathol. 2015;8(5):4782–90.26191168
125. Koo T Cho BJ Kim DH Park JM Choi EJ Kim HH MicroRNA-200c increases radiosensitivity of human cancer cells with activated EGFR-associated signaling Oncotarget 2017 8 39 65457 68 10.18632/oncotarget.18924 29029445
Koo T, Cho BJ, Kim DH, Park JM, Choi EJ, Kim HH, et al. MicroRNA-200c increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Oncotarget. 2017;8(39):65457–68.29029445 10.18632/oncotarget.18924
126. Li G Huang M Cai Y Ke Y Yang Y Sun X miR–141 inhibits glioma vasculogenic mimicry by controlling EphA2 expression Mol Med Rep 2018 18 2 1395 404 29901110
Li G, Huang M, Cai Y, Ke Y, Yang Y, Sun X. miR–141 inhibits glioma vasculogenic mimicry by controlling EphA2 expression. Mol Med Rep. 2018;18(2):1395–404.29901110
127. Li R Yuan W Mei W Yang K Chen Z MicroRNA 520d-3p inhibits gastric cancer cell proliferation, migration, and invasion by downregulating EphA2 expression Mol Cell Biochem 2014 396 1–2 295 305 10.1007/s11010-014-2164-6 25063221
Li R, Yuan W, Mei W, Yang K, Chen Z. MicroRNA 520d-3p inhibits gastric cancer cell proliferation, migration, and invasion by downregulating EphA2 expression. Mol Cell Biochem. 2014;396(1–2):295–305.25063221 10.1007/s11010-014-2164-6
128. Tang L Hu H He Y McLeod HL Xiao D Chen P The relationship between miR-302b and EphA2 and their clinical significance in gastric cancer J Cancer 2018 9 17 3109 16 10.7150/jca.25235 30210634
Tang L, Hu H, He Y, McLeod HL, Xiao D, Chen P, et al. The relationship between miR-302b and EphA2 and their clinical significance in gastric cancer. J Cancer. 2018;9(17):3109–16.30210634 10.7150/jca.25235
129. Gong S Li Y Lv L Men W Restored microRNA-519a enhances the radiosensitivity of non-small cell lung cancer via suppressing EphA2 Gene Ther 2022 29 10–11 588 600 10.1038/s41434-020-00213-x 33414521
Gong S, Li Y, Lv L, Men W. Restored microRNA-519a enhances the radiosensitivity of non-small cell lung cancer via suppressing EphA2. Gene Ther. 2022;29(10–11):588–600.33414521 10.1038/s41434-020-00213-x
130. Liu B Sun W Gao W Li L Cao Z Yang X microRNA-451a promoter methylation regulated by DNMT3B expedites bladder cancer development via the EPHA2/PI3K/AKT axis BMC Cancer 2020 20 1 1019 10.1186/s12885-020-07523-8 33087088
Liu B, Sun W, Gao W, Li L, Cao Z, Yang X, et al. microRNA-451a promoter methylation regulated by DNMT3B expedites bladder cancer development via the EPHA2/PI3K/AKT axis. BMC Cancer. 2020;20(1):1019.33087088 10.1186/s12885-020-07523-8
131. Li R Hu Z Wang Z Zhu T Wang G Gao B miR-125a-5p promotes gastric cancer growth and invasion by regulating the Hippo pathway J Clin Lab Anal 2021 35 12 e24078 10.1002/jcla.24078 34708891
Li R, Hu Z, Wang Z, Zhu T, Wang G, Gao B, et al. miR-125a-5p promotes gastric cancer growth and invasion by regulating the Hippo pathway. J Clin Lab Anal. 2021;35(12):e24078.34708891 10.1002/jcla.24078
132. Cui S Wu Q Liu M Su M Liu S Shao L EphA2 super-enhancer promotes tumor progression by recruiting FOSL2 and TCF7L2 to activate the target gene EphA2 Cell Death Dis 2021 12 3 264 10.1038/s41419-021-03538-6 33712565
Cui S, Wu Q, Liu M, Su M, Liu S, Shao L, et al. EphA2 super-enhancer promotes tumor progression by recruiting FOSL2 and TCF7L2 to activate the target gene EphA2. Cell Death Dis. 2021;12(3):264.33712565 10.1038/s41419-021-03538-6
133. Hnisz D Abraham BJ Lee TI Lau A Saint-André V Sigova AA Super-enhancers in the control of cell identity and disease Cell 2013 155 4 934 47 10.1016/j.cell.2013.09.053 24119843
Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, et al. Super-enhancers in the control of cell identity and disease. Cell. 2013;155(4):934–47.24119843 10.1016/j.cell.2013.09.053
134. Whyte WA Orlando DA Hnisz D Abraham BJ Lin CY Kagey MH Master transcription factors and mediator establish super-enhancers at key cell identity genes Cell 2013 153 2 307 19 10.1016/j.cell.2013.03.035 23582322
Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153(2):307–19.23582322 10.1016/j.cell.2013.03.035
135. Jin R Lin H Li G Xu J Shi L Chang C TR(4) nuclear receptor suppresses HCC cell invasion via downregulating the EphA2 expression Cell Death Dis 2018 9 3 283 10.1038/s41419-018-0287-5 29449527
Jin R, Lin H, Li G, Xu J, Shi L, Chang C, et al. TR(4) nuclear receptor suppresses HCC cell invasion via downregulating the EphA2 expression. Cell Death Dis. 2018;9(3):283.29449527 10.1038/s41419-018-0287-5
136. Joseph R, Dasari SK, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C et al. EphA2- and HDAC-Targeted combination therapy in Endometrial Cancer. Int J Mol Sci. 2024;25(2).
137. Wykosky J Palma E Gibo DM Ringler S Turner CP Debinski W Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor Oncogene 2008 27 58 7260 73 10.1038/onc.2008.328 18794797
Wykosky J, Palma E, Gibo DM, Ringler S, Turner CP, Debinski W. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene. 2008;27(58):7260–73.18794797 10.1038/onc.2008.328
138. Xu Q Lin WC Petit RS Groves JT EphA2 receptor activation by monomeric Ephrin-A1 on supported membranes Biophys J 2011 101 11 2731 9 10.1016/j.bpj.2011.10.039 22261062
Xu Q, Lin WC, Petit RS, Groves JT. EphA2 receptor activation by monomeric Ephrin-A1 on supported membranes. Biophys J. 2011;101(11):2731–9.22261062 10.1016/j.bpj.2011.10.039
139. Koolpe M Dail M Pasquale EB An ephrin mimetic peptide that selectively targets the EphA2 receptor J Biol Chem 2002 277 49 46974 9 10.1074/jbc.M208495200 12351647
Koolpe M, Dail M, Pasquale EB. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem. 2002;277(49):46974–9.12351647 10.1074/jbc.M208495200
140. Gomez-Soler M Petersen Gehring M Lechtenberg BC Zapata-Mercado E Hristova K Pasquale EB Engineering Nanomolar peptide ligands that differentially modulate EphA2 receptor signaling J Biol Chem 2019 294 22 8791 805 10.1074/jbc.RA119.008213 31015204
Gomez-Soler M, Petersen Gehring M, Lechtenberg BC, Zapata-Mercado E, Hristova K, Pasquale EB. Engineering Nanomolar peptide ligands that differentially modulate EphA2 receptor signaling. J Biol Chem. 2019;294(22):8791–805.31015204 10.1074/jbc.RA119.008213
141. Alves DS, Westerfield JM, Shi X, Nguyen VP, Stefanski KM, Booth KR et al. A novel pH-dependent membrane peptide that binds to EphA2 and inhibits cell migration. Elife. 2018;7.
142. Westerfield JM Sahoo AR Alves DS Grau B Cameron A Maxwell M Conformational clamping by a membrane ligand activates the EphA2 receptor J Mol Biol 2021 433 18 167144 10.1016/j.jmb.2021.167144 34229012
Westerfield JM, Sahoo AR, Alves DS, Grau B, Cameron A, Maxwell M, et al. Conformational clamping by a membrane ligand activates the EphA2 receptor. J Mol Biol. 2021;433(18):167144.34229012 10.1016/j.jmb.2021.167144
143. Mercurio FA Di Natale C Pirone L Iannitti R Marasco D Pedone EM The Sam-Sam interaction between Ship2 and the EphA2 receptor: design and analysis of peptide inhibitors Sci Rep 2017 7 1 17474 10.1038/s41598-017-17684-5 29234063
Mercurio FA, Di Natale C, Pirone L, Iannitti R, Marasco D, Pedone EM, et al. The Sam-Sam interaction between Ship2 and the EphA2 receptor: design and analysis of peptide inhibitors. Sci Rep. 2017;7(1):17474.29234063 10.1038/s41598-017-17684-5
144. Mercurio FA Di Natale C Pirone L Marasco D Calce E Vincenzi M Design and analysis of EphA2-SAM peptide ligands: a multi-disciplinary screening approach Bioorg Chem 2019 84 434 43 10.1016/j.bioorg.2018.12.009 30576907
Mercurio FA, Di Natale C, Pirone L, Marasco D, Calce E, Vincenzi M, et al. Design and analysis of EphA2-SAM peptide ligands: a multi-disciplinary screening approach. Bioorg Chem. 2019;84:434–43.30576907 10.1016/j.bioorg.2018.12.009
145. Mercurio FA Pirone L Di Natale C Marasco D Pedone EM Leone M Sam domain-based stapled peptides: structural analysis and interaction studies with the Sam domains from the EphA2 receptor and the lipid phosphatase Ship2 Bioorg Chem 2018 80 602 10 10.1016/j.bioorg.2018.07.013 30036816
Mercurio FA, Pirone L, Di Natale C, Marasco D, Pedone EM, Leone M. Sam domain-based stapled peptides: structural analysis and interaction studies with the Sam domains from the EphA2 receptor and the lipid phosphatase Ship2. Bioorg Chem. 2018;80:602–10.30036816 10.1016/j.bioorg.2018.07.013
146. Carles-Kinch K Kilpatrick KE Stewart JC Kinch MS Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior Cancer Res 2002 62 10 2840 7 12019162
Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res. 2002;62(10):2840–7.12019162
147. Coffman KT Hu M Carles-Kinch K Tice D Donacki N Munyon K Differential EphA2 epitope display on normal versus malignant cells Cancer Res 2003 63 22 7907 12 14633720
Coffman KT, Hu M, Carles-Kinch K, Tice D, Donacki N, Munyon K, et al. Differential EphA2 epitope display on normal versus malignant cells. Cancer Res. 2003;63(22):7907–12.14633720
148. Ansuini H Meola A Gunes Z Paradisi V Pezzanera M Acali S Anti-EphA2 antibodies with distinct in Vitro Properties have equal in vivo efficacy in pancreatic Cancer J Oncol 2009 2009 951917 10.1155/2009/951917 20130824
Ansuini H, Meola A, Gunes Z, Paradisi V, Pezzanera M, Acali S, et al. Anti-EphA2 antibodies with distinct in Vitro Properties have equal in vivo efficacy in pancreatic Cancer. J Oncol. 2009;2009:951917.20130824 10.1155/2009/951917
149. Jackson D Gooya J Mao S Kinneer K Xu L Camara M A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo Cancer Res 2008 68 22 9367 74 10.1158/0008-5472.CAN-08-1933 19010911
Jackson D, Gooya J, Mao S, Kinneer K, Xu L, Camara M, et al. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res. 2008;68(22):9367–74.19010911 10.1158/0008-5472.CAN-08-1933
150. Hasegawa J Sue M Yamato M Ichikawa J Ishida S Shibutani T Novel anti-EPHA2 antibody, DS-8895a for cancer treatment Cancer Biol Ther 2016 17 11 1158 67 10.1080/15384047.2016.1235663 27653549
Hasegawa J, Sue M, Yamato M, Ichikawa J, Ishida S, Shibutani T, et al. Novel anti-EPHA2 antibody, DS-8895a for cancer treatment. Cancer Biol Ther. 2016;17(11):1158–67.27653549 10.1080/15384047.2016.1235663
151. Sakamoto A Kato K Hasegawa T Ikeda S An agonistic antibody to EPHA2 exhibits Antitumor effects on Human Melanoma cells Anticancer Res 2018 38 6 3273 82 10.21873/anticanres.12592 29848674
Sakamoto A, Kato K, Hasegawa T, Ikeda S. An agonistic antibody to EPHA2 exhibits Antitumor effects on Human Melanoma cells. Anticancer Res. 2018;38(6):3273–82.29848674 10.21873/anticanres.12592
152. Dobrzanski P Hunter K Jones-Bolin S Chang H Robinson C Pritchard S Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist Cancer Res 2004 64 3 910 9 10.1158/0008-5472.CAN-3430-2 14871820
Dobrzanski P, Hunter K, Jones-Bolin S, Chang H, Robinson C, Pritchard S, et al. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res. 2004;64(3):910–9.14871820 10.1158/0008-5472.CAN-3430-2
153. Giorgio C Hassan Mohamed I Flammini L Barocelli E Incerti M Lodola A Lithocholic acid is an eph-ephrin ligand interfering with eph-kinase activation PLoS ONE 2011 6 3 e18128 10.1371/journal.pone.0018128 21479221
Giorgio C, Hassan Mohamed I, Flammini L, Barocelli E, Incerti M, Lodola A, et al. Lithocholic acid is an eph-ephrin ligand interfering with eph-kinase activation. PLoS ONE. 2011;6(3):e18128.21479221 10.1371/journal.pone.0018128
154. Tognolini M Incerti M Hassan-Mohamed I Giorgio C Russo S Bruni R Structure-activity relationships and mechanism of action of eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor ChemMedChem 2012 7 6 1071 83 10.1002/cmdc.201200102 22529030
Tognolini M, Incerti M, Hassan-Mohamed I, Giorgio C, Russo S, Bruni R, et al. Structure-activity relationships and mechanism of action of eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor. ChemMedChem. 2012;7(6):1071–83.22529030 10.1002/cmdc.201200102
155. Giorgio C Russo S Incerti M Bugatti A Vacondio F Barocelli E Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis Biochem Pharmacol 2016 99 18 30 10.1016/j.bcp.2015.10.006 26462575
Giorgio C, Russo S, Incerti M, Bugatti A, Vacondio F, Barocelli E, et al. Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis. Biochem Pharmacol. 2016;99:18–30.26462575 10.1016/j.bcp.2015.10.006
156. Tognolini M Incerti M Pala D Russo S Castelli R Hassan-Mohamed I Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists ChemMedChem 2014 9 1 67 72 10.1002/cmdc.201300305 24115725
Tognolini M, Incerti M, Pala D, Russo S, Castelli R, Hassan-Mohamed I, et al. Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists. ChemMedChem. 2014;9(1):67–72.24115725 10.1002/cmdc.201300305
157. Incerti M Tognolini M Russo S Pala D Giorgio C Hassan-Mohamed I Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor J Med Chem 2013 56 7 2936 47 10.1021/jm301890k 23489211
Incerti M, Tognolini M, Russo S, Pala D, Giorgio C, Hassan-Mohamed I, et al. Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013;56(7):2936–47.23489211 10.1021/jm301890k
158. Hassan-Mohamed I Giorgio C Incerti M Russo S Pala D Pasquale EB UniPR129 is a competitive small molecule eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations Br J Pharmacol 2014 171 23 5195 208 10.1111/bph.12669 24597515
Hassan-Mohamed I, Giorgio C, Incerti M, Russo S, Pala D, Pasquale EB, et al. UniPR129 is a competitive small molecule eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol. 2014;171(23):5195–208.24597515 10.1111/bph.12669
159. Festuccia C Gravina GL Giorgio C Mancini A Pellegrini C Colapietro A UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice Oncotarget 2018 9 36 24347 63 10.18632/oncotarget.25272 29849945
Festuccia C, Gravina GL, Giorgio C, Mancini A, Pellegrini C, Colapietro A, et al. UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice. Oncotarget. 2018;9(36):24347–63.29849945 10.18632/oncotarget.25272
160. Ferrari FR Giorgio C Zappia A Ballabeni V Bertoni S Barocelli E Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: a successful application of target hopping approach Biochem Pharmacol 2023 209 115452 10.1016/j.bcp.2023.115452 36792038
Ferrari FR, Giorgio C, Zappia A, Ballabeni V, Bertoni S, Barocelli E, et al. Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: a successful application of target hopping approach. Biochem Pharmacol. 2023;209:115452.36792038 10.1016/j.bcp.2023.115452
161. Buettner R Mesa T Vultur A Lee F Jove R Inhibition of src family kinases with dasatinib blocks migration and invasion of human melanoma cells Mol Cancer Res 2008 6 11 1766 74 10.1158/1541-7786.MCR-08-0169 19010823
Buettner R, Mesa T, Vultur A, Lee F, Jove R. Inhibition of src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res. 2008;6(11):1766–74.19010823 10.1158/1541-7786.MCR-08-0169
162. Huang F Reeves K Han X Fairchild C Platero S Wong TW Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection Cancer Res 2007 67 5 2226 38 10.1158/0008-5472.CAN-06-3633 17332353
Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007;67(5):2226–38.17332353 10.1158/0008-5472.CAN-06-3633
163. Chang Q Jorgensen C Pawson T Hedley DW Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer Br J Cancer 2008 99 7 1074 82 10.1038/sj.bjc.6604676 18797457
Chang Q, Jorgensen C, Pawson T, Hedley DW. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer. 2008;99(7):1074–82.18797457 10.1038/sj.bjc.6604676
164. Miller AA Pang H Hodgson L Ramnath N Otterson GA Kelley MJ A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602) J Thorac Oncol 2010 5 3 380 4 10.1097/JTO.0b013e3181cee36e 20087228
Miller AA, Pang H, Hodgson L, Ramnath N, Otterson GA, Kelley MJ, et al. A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). J Thorac Oncol. 2010;5(3):380–4.20087228 10.1097/JTO.0b013e3181cee36e
165. Duckett DR Cameron MD Metabolism considerations for kinase inhibitors in cancer treatment Expert Opin Drug Metab Toxicol 2010 6 10 1175 93 10.1517/17425255.2010.506873 20684746
Duckett DR, Cameron MD. Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin Drug Metab Toxicol. 2010;6(10):1175–93.20684746 10.1517/17425255.2010.506873
166. Karaman MW Herrgard S Treiber DK Gallant P Atteridge CE Campbell BT A quantitative analysis of kinase inhibitor selectivity Nat Biotechnol 2008 26 1 127 32 10.1038/nbt1358 18183025
Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127–32.18183025 10.1038/nbt1358
167. Heinzlmeir S Lohse J Treiber T Kudlinzki D Linhard V Gande SL Chemoproteomics-aided Medicinal Chemistry for the Discovery of EPHA2 inhibitors ChemMedChem 2017 12 12 999 1011 10.1002/cmdc.201700217 28544567
Heinzlmeir S, Lohse J, Treiber T, Kudlinzki D, Linhard V, Gande SL, et al. Chemoproteomics-aided Medicinal Chemistry for the Discovery of EPHA2 inhibitors. ChemMedChem. 2017;12(12):999–1011.28544567 10.1002/cmdc.201700217
168. Ho HK Chua BT Wong W Lim KS Teo V Ong HT Benzylidene-indolinones are effective as multi-targeted kinase inhibitor therapeutics against hepatocellular carcinoma Mol Oncol 2014 8 7 1266 77 10.1016/j.molonc.2014.04.008 24839937
Ho HK, Chua BT, Wong W, Lim KS, Teo V, Ong HT, et al. Benzylidene-indolinones are effective as multi-targeted kinase inhibitor therapeutics against hepatocellular carcinoma. Mol Oncol. 2014;8(7):1266–77.24839937 10.1016/j.molonc.2014.04.008
169. Dolan M Mastri M Tracz A Christensen JG Chatta G Ebos JML Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance PLoS ONE 2019 14 8 e0220101 10.1371/journal.pone.0220101 31369645
Dolan M, Mastri M, Tracz A, Christensen JG, Chatta G, Ebos JML. Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance. PLoS ONE. 2019;14(8):e0220101.31369645 10.1371/journal.pone.0220101
170. Patwardhan PP Ivy KS Musi E de Stanchina E Schwartz GK Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma Oncotarget 2016 7 4 4093 109 10.18632/oncotarget.6547 26675259
Patwardhan PP, Ivy KS, Musi E, de Stanchina E, Schwartz GK. Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. Oncotarget. 2016;7(4):4093–109.26675259 10.18632/oncotarget.6547
171. Bauer T Cho BC Heist R Bazhenova L Werner T Goel S First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors Invest New Drugs 2022 40 5 990 1000 10.1007/s10637-022-01274-y 35767205
Bauer T, Cho BC, Heist R, Bazhenova L, Werner T, Goel S, et al. First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors. Invest New Drugs. 2022;40(5):990–1000.35767205 10.1007/s10637-022-01274-y
172. Amato KR Wang S Tan L Hastings AK Song W Lovly CM EPHA2 blockade overcomes Acquired Resistance to EGFR kinase inhibitors in Lung Cancer Cancer Res 2016 76 2 305 18 10.1158/0008-5472.CAN-15-0717 26744526
Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, et al. EPHA2 blockade overcomes Acquired Resistance to EGFR kinase inhibitors in Lung Cancer. Cancer Res. 2016;76(2):305–18.26744526 10.1158/0008-5472.CAN-15-0717
173. Xiang YP Xiao T Li QG Lu SS Zhu W Liu YY Y772 phosphorylation of EphA2 is responsible for EphA2-dependent NPC nasopharyngeal carcinoma growth by Shp2/Erk-1/2 signaling pathway Cell Death Dis 2020 11 8 709 10.1038/s41419-020-02831-0 32848131
Xiang YP, Xiao T, Li QG, Lu SS, Zhu W, Liu YY, et al. Y772 phosphorylation of EphA2 is responsible for EphA2-dependent NPC nasopharyngeal carcinoma growth by Shp2/Erk-1/2 signaling pathway. Cell Death Dis. 2020;11(8):709.32848131 10.1038/s41419-020-02831-0
174. Li X Li D Ma R ALW-II-41-27, an EphA2 inhibitor, inhibits proliferation, migration and invasion of cervical cancer cells via inhibition of the RhoA/ROCK pathway Oncol Lett 2022 23 4 129 10.3892/ol.2022.13249 35251349
Li X, Li D, Ma R. ALW-II-41-27, an EphA2 inhibitor, inhibits proliferation, migration and invasion of cervical cancer cells via inhibition of the RhoA/ROCK pathway. Oncol Lett. 2022;23(4):129.35251349 10.3892/ol.2022.13249
175. Wang H Hou W Perera A Bettler C Beach JR Ding X Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling Cell Rep 2021 34 8 108765 10.1016/j.celrep.2021.108765 33626345
Wang H, Hou W, Perera A, Bettler C, Beach JR, Ding X, et al. Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling. Cell Rep. 2021;34(8):108765.33626345 10.1016/j.celrep.2021.108765
176. Rezaie E Amani J Bidmeshki Pour A Mahmoodzadeh Hosseini H A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; high in vitro anti-cancer potency Eur J Pharmacol 2020 870 172912 10.1016/j.ejphar.2020.172912 31926992
Rezaie E, Amani J, Bidmeshki Pour A, Mahmoodzadeh Hosseini H. A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; high in vitro anti-cancer potency. Eur J Pharmacol. 2020;870:172912.31926992 10.1016/j.ejphar.2020.172912
177. Wykosky J Gibo DM Debinski W A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells Mol Cancer Ther 2007 6 12 Pt 1 3208 18 10.1158/1535-7163.MCT-07-0200 18089715
Wykosky J, Gibo DM, Debinski W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Mol Cancer Ther. 2007;6(12 Pt 1):3208–18.18089715 10.1158/1535-7163.MCT-07-0200
178. Lee JW Stone RL Lee SJ Nam EJ Roh JW Nick AM EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma Clin Cancer Res 2010 16 9 2562 70 10.1158/1078-0432.CCR-10-0017 20388851
Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010;16(9):2562–70.20388851 10.1158/1078-0432.CCR-10-0017
179. Lee JW Han HD Shahzad MM Kim SW Mangala LS Nick AM EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma J Natl Cancer Inst 2009 101 17 1193 205 10.1093/jnci/djp231 19641174
Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, et al. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009;101(17):1193–205.19641174 10.1093/jnci/djp231
180. Annunziata CM Kohn EC LoRusso P Houston ND Coleman RL Buzoianu M Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors Invest New Drugs 2013 31 1 77 84 10.1007/s10637-012-9801-2 22370972
Annunziata CM, Kohn EC, LoRusso P, Houston ND, Coleman RL, Buzoianu M, et al. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs. 2013;31(1):77–84.22370972 10.1007/s10637-012-9801-2
181. Mudd GE Brown A Chen L van Rietschoten K Watcham S Teufel DP Identification and optimization of EphA2-Selective bicycles for the delivery of cytotoxic payloads J Med Chem 2020 63 8 4107 16 10.1021/acs.jmedchem.9b02129 32202781
Mudd GE, Brown A, Chen L, van Rietschoten K, Watcham S, Teufel DP, et al. Identification and optimization of EphA2-Selective bicycles for the delivery of cytotoxic payloads. J Med Chem. 2020;63(8):4107–16.32202781 10.1021/acs.jmedchem.9b02129
182. Bicyclic Peptide Makes Targeting EphA2 Possible Cancer Discov 2021 11 12 2951 2
Bicyclic Peptide Makes Targeting EphA2 Possible. Cancer Discov. 2021;11(12):2951–2.
183. Wang S Placzek WJ Stebbins JL Mitra S Noberini R Koolpe M Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells J Med Chem 2012 55 5 2427 36 10.1021/jm201743s 22329578
Wang S, Placzek WJ, Stebbins JL, Mitra S, Noberini R, Koolpe M, et al. Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells. J Med Chem. 2012;55(5):2427–36.22329578 10.1021/jm201743s
184. Wang S Noberini R Stebbins JL Das S Zhang Z Wu B Targeted delivery of paclitaxel to EphA2-expressing cancer cells Clin Cancer Res 2013 19 1 128 37 10.1158/1078-0432.CCR-12-2654 23155185
Wang S, Noberini R, Stebbins JL, Das S, Zhang Z, Wu B, et al. Targeted delivery of paclitaxel to EphA2-expressing cancer cells. Clin Cancer Res. 2013;19(1):128–37.23155185 10.1158/1078-0432.CCR-12-2654
185. Barile E Wang S Das SK Noberini R Dahl R Stebbins JL Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system ChemMedChem 2014 9 7 1403 12 10.1002/cmdc.201400067 24677792
Barile E, Wang S, Das SK, Noberini R, Dahl R, Stebbins JL, et al. Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system. ChemMedChem. 2014;9(7):1403–12.24677792 10.1002/cmdc.201400067
186. Wu B Wang S De SK Barile E Quinn BA Zharkikh I Design and characterization of Novel EphA2 agonists for targeted delivery of chemotherapy to Cancer cells Chem Biol 2015 22 7 876 87 10.1016/j.chembiol.2015.06.011 26165155
Wu B, Wang S, De SK, Barile E, Quinn BA, Zharkikh I, et al. Design and characterization of Novel EphA2 agonists for targeted delivery of chemotherapy to Cancer cells. Chem Biol. 2015;22(7):876–87.26165155 10.1016/j.chembiol.2015.06.011
187. Salem AF Wang S Billet S Chen JF Udompholkul P Gambini L Reduction of circulating Cancer cells and metastases in breast-Cancer models by a potent EphA2-Agonistic peptide-drug Conjugate J Med Chem 2018 61 5 2052 61 10.1021/acs.jmedchem.7b01837 29470068
Salem AF, Wang S, Billet S, Chen JF, Udompholkul P, Gambini L, et al. Reduction of circulating Cancer cells and metastases in breast-Cancer models by a potent EphA2-Agonistic peptide-drug Conjugate. J Med Chem. 2018;61(5):2052–61.29470068 10.1021/acs.jmedchem.7b01837
188. Quinn BA Wang S Barile E Das SK Emdad L Sarkar D Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine Oncotarget 2016 7 13 17103 10 10.18632/oncotarget.7931 26959746
Quinn BA, Wang S, Barile E, Das SK, Emdad L, Sarkar D, et al. Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. Oncotarget. 2016;7(13):17103–10.26959746 10.18632/oncotarget.7931
189. Baggio C Udompholkul P Gambini L Pellecchia M Targefrin A potent Agent targeting the ligand binding domain of EphA2 J Med Chem 2022 65 22 15443 56 10.1021/acs.jmedchem.2c01391 36331527
Baggio C, Udompholkul P, Gambini L, Pellecchia M, Targefrin. A potent Agent targeting the ligand binding domain of EphA2. J Med Chem. 2022;65(22):15443–56.36331527 10.1021/acs.jmedchem.2c01391
190. Fu Y, Rathod D, Abo-Ali EM, Dukhande VV, Patel K. EphA2-Receptor targeted PEGylated nanoliposomes for the treatment of BRAF(V600E) mutated parent- and Vemurafenib-Resistant Melanoma. Pharmaceutics. 2019;11(10).
191. Haghiralsadat F Amoabediny G Sheikhha MH Zandieh-Doulabi B Naderinezhad S Helder MN New liposomal doxorubicin nanoformulation for osteosarcoma: drug release kinetic study based on thermo and pH sensitivity Chem Biol Drug Des 2017 90 3 368 79 10.1111/cbdd.12953 28120466
Haghiralsadat F, Amoabediny G, Sheikhha MH, Zandieh-Doulabi B, Naderinezhad S, Helder MN, et al. New liposomal doxorubicin nanoformulation for osteosarcoma: drug release kinetic study based on thermo and pH sensitivity. Chem Biol Drug Des. 2017;90(3):368–79.28120466 10.1111/cbdd.12953
192. Haghiralsadat F Amoabediny G Naderinezhad S Zandieh-Doulabi B Forouzanfar T Helder MN Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance Int J Nanomed 2018 13 3853 66 10.2147/IJN.S150017
Haghiralsadat F, Amoabediny G, Naderinezhad S, Zandieh-Doulabi B, Forouzanfar T, Helder MN. Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance. Int J Nanomed. 2018;13:3853–66.10.2147/IJN.S150017
193. Carofiglio M Mesiano G Rosso G Conte M Zuccheri M Pignochino Y Targeted lipid-coated ZnO nanoparticles coupled with ultrasound: a sonodynamic approach for the treatment of osteosarcoma as 3D spheroid models Mater Today Commun 2024 40 109826 10.1016/j.mtcomm.2024.109826
Carofiglio M, Mesiano G, Rosso G, Conte M, Zuccheri M, Pignochino Y, et al. Targeted lipid-coated ZnO nanoparticles coupled with ultrasound: a sonodynamic approach for the treatment of osteosarcoma as 3D spheroid models. Mater Today Commun. 2024;40:109826.10.1016/j.mtcomm.2024.109826
194. Kamoun W, Swindell E, Pien C, Luus L, Cain J, Pham M et al. Targeting EphA2 in bladder Cancer using a novel antibody-Directed Nanotherapeutic. Pharmaceutics. 2020;12(10).
195. Kamoun WS Dugast AS Suchy JJ Grabow S Fulton RB Sampson JF Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted nanoliposomal taxane, and PD-1 inhibitors in preclinical Tumor models Mol Cancer Ther 2020 19 1 270 81 10.1158/1535-7163.MCT-19-0414 31597714
Kamoun WS, Dugast AS, Suchy JJ, Grabow S, Fulton RB, Sampson JF, et al. Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted nanoliposomal taxane, and PD-1 inhibitors in preclinical Tumor models. Mol Cancer Ther. 2020;19(1):270–81.31597714 10.1158/1535-7163.MCT-19-0414
196. Marc S, Ernstoff WWM, Tsai FY-C, Munster PN, Zhang T, Kamoun W, Pipas JM, Chen S. Sergio Santillana, and Vasileios Askoxylakis. A phase 1 study 1325 evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid 1326 tumors. J Clin Oncol. 2018;36.
197. Pasquale EB Eph-ephrin bidirectional signaling in physiology and disease Cell 2008 133 1 38 52 10.1016/j.cell.2008.03.011 18394988
Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell. 2008;133(1):38–52.18394988 10.1016/j.cell.2008.03.011
198. Neuber C Belter B Mamat C Pietzsch J Radiopharmacologist’s and Radiochemist’s view on targeting the Eph/Ephrin receptor tyrosine kinase system ACS Omega 2020 5 27 16318 31 10.1021/acsomega.0c01058 32685795
Neuber C, Belter B, Mamat C, Pietzsch J. Radiopharmacologist’s and Radiochemist’s view on targeting the Eph/Ephrin receptor tyrosine kinase system. ACS Omega. 2020;5(27):16318–31.32685795 10.1021/acsomega.0c01058
199. Cai W Ebrahimnejad A Chen K Cao Q Li ZB Tice DA Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice Eur J Nucl Med Mol Imaging 2007 34 12 2024 36 10.1007/s00259-007-0503-5 17673999
Cai W, Ebrahimnejad A, Chen K, Cao Q, Li ZB, Tice DA, et al. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging. 2007;34(12):2024–36.17673999 10.1007/s00259-007-0503-5
200. Puttick S Stringer BW Day BW Bruce ZC Ensbey KS Mardon K EphA2 as a diagnostic imaging target in Glioblastoma: a Positron Emission Tomography/Magnetic resonance imaging study Mol Imaging 2015 14 385 99 10.2310/7290.2015.00008 26218510
Puttick S, Stringer BW, Day BW, Bruce ZC, Ensbey KS, Mardon K, et al. EphA2 as a diagnostic imaging target in Glioblastoma: a Positron Emission Tomography/Magnetic resonance imaging study. Mol Imaging. 2015;14:385–99.26218510 10.2310/7290.2015.00008
201. Pyo A You SH Sik Kim H Young Kim J Min JJ Kim DY Production of (64)Cu-labeled monobody for imaging of human EphA2-expressing tumors Bioorg Med Chem Lett 2020 30 14 127262 10.1016/j.bmcl.2020.127262 32527560
Pyo A, You SH, Sik Kim H, Young Kim J, Min JJ, Kim DY, et al. Production of (64)Cu-labeled monobody for imaging of human EphA2-expressing tumors. Bioorg Med Chem Lett. 2020;30(14):127262.32527560 10.1016/j.bmcl.2020.127262
202. Burvenich IJ Parakh S Gan HK Lee FT Guo N Rigopoulos A Molecular imaging and quantitation of EphA2 expression in Xenograft models with 89Zr-DS-8895a J Nucl Med 2016 57 6 974 80 10.2967/jnumed.115.169839 26940768
Burvenich IJ, Parakh S, Gan HK, Lee FT, Guo N, Rigopoulos A, et al. Molecular imaging and quantitation of EphA2 expression in Xenograft models with 89Zr-DS-8895a. J Nucl Med. 2016;57(6):974–80.26940768 10.2967/jnumed.115.169839
203. Shitara K Satoh T Iwasa S Yamaguchi K Muro K Komatsu Y Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors J Immunother Cancer 2019 7 1 219 10.1186/s40425-019-0679-9 31412935
Shitara K, Satoh T, Iwasa S, Yamaguchi K, Muro K, Komatsu Y, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors. J Immunother Cancer. 2019;7(1):219.31412935 10.1186/s40425-019-0679-9
204. Gan HK Parakh S Lee FT Tebbutt NC Ameratunga M Lee ST A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers Invest New Drugs 2022 40 4 747 55 10.1007/s10637-022-01237-3 35404015
Gan HK, Parakh S, Lee FT, Tebbutt NC, Ameratunga M, Lee ST, et al. A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers. Invest New Drugs. 2022;40(4):747–55.35404015 10.1007/s10637-022-01237-3
205. Furukawa T Kimura H Sasaki M Yamada T Iwasawa T Yagi Y Novel [ (111) in]In-BnDTPA-EphA2-230-1 antibody for single-Photon Emission computed Tomography Imaging Tracer Targeting of EphA2 ACS Omega 2023 8 7 7030 5 10.1021/acsomega.2c07849 36844571
Furukawa T, Kimura H, Sasaki M, Yamada T, Iwasawa T, Yagi Y, et al. Novel [ (111) in]In-BnDTPA-EphA2-230-1 antibody for single-Photon Emission computed Tomography Imaging Tracer Targeting of EphA2. ACS Omega. 2023;8(7):7030–5.36844571 10.1021/acsomega.2c07849
206. Pretze M Mosch B Bergmann R Steinbach J Pietzsch J Mamat C Radiofluorination and first radiopharmacological characterization of a SWLAY peptide-based ligand targeting EphA2 J Label Comp Radiopharm 2014 57 11 660 5 10.1002/jlcr.3237
Pretze M, Mosch B, Bergmann R, Steinbach J, Pietzsch J, Mamat C. Radiofluorination and first radiopharmacological characterization of a SWLAY peptide-based ligand targeting EphA2. J Label Comp Radiopharm. 2014;57(11):660–5.10.1002/jlcr.3237
207. Liu Y Lan X Wu T Lang J Jin X Sun X 99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor Nucl Med Biol 2014 41 6 450 6 10.1016/j.nucmedbio.2014.03.020 24768147
Liu Y, Lan X, Wu T, Lang J, Jin X, Sun X, et al. (99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor. Nucl Med Biol. 2014;41(6):450–6.24768147 10.1016/j.nucmedbio.2014.03.020
208. Furukawa T Kimura H Torimoto H Yagi Y Kawashima H Arimitsu K A putative single-Photon Emission CT Imaging Tracer for Erythropoietin-Producing Hepatocellular A2 receptor ACS Med Chem Lett 2021 12 8 1238 44 10.1021/acsmedchemlett.1c00030 34413953
Furukawa T, Kimura H, Torimoto H, Yagi Y, Kawashima H, Arimitsu K, et al. A putative single-Photon Emission CT Imaging Tracer for Erythropoietin-Producing Hepatocellular A2 receptor. ACS Med Chem Lett. 2021;12(8):1238–44.34413953 10.1021/acsmedchemlett.1c00030
209. Yang Y Cancer immunotherapy: harnessing the immune system to battle cancer J Clin Invest 2015 125 9 3335 7 10.1172/JCI83871 26325031
Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125(9):3335–7.26325031 10.1172/JCI83871
210. Dotti G Gottschalk S Savoldo B Brenner MK Design and development of therapies using chimeric antigen receptor-expressing T cells Immunol Rev 2014 257 1 107 26 10.1111/imr.12131 24329793
Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257(1):107–26.24329793 10.1111/imr.12131
211. Li N Liu S Sun M Chen W Xu X Zeng Z Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-small Cell Lung Cancer Transl Oncol 2018 11 1 11 7 10.1016/j.tranon.2017.10.009 29132013
Li N, Liu S, Sun M, Chen W, Xu X, Zeng Z, et al. Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-small Cell Lung Cancer. Transl Oncol. 2018;11(1):11–7.29132013 10.1016/j.tranon.2017.10.009
212. Shi H Yu F Mao Y Ju Q Wu Y Bai W EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma J Thorac Dis 2018 10 5 2779 88 10.21037/jtd.2018.04.91 29997940
Shi H, Yu F, Mao Y, Ju Q, Wu Y, Bai W, et al. EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma. J Thorac Dis. 2018;10(5):2779–88.29997940 10.21037/jtd.2018.04.91
213. Chow KK Naik S Kakarla S Brawley VS Shaffer DR Yi Z T cells redirected to EphA2 for the immunotherapy of glioblastoma Mol Ther 2013 21 3 629 37 10.1038/mt.2012.210 23070117
Chow KK, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther. 2013;21(3):629–37.23070117 10.1038/mt.2012.210
214. Hsu K Middlemiss S Saletta F Gottschalk S McCowage GB Kramer B Chimeric Antigen receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours Cancer Gene Ther 2021 28 3–4 321 34 10.1038/s41417-020-00221-4 32873870
Hsu K, Middlemiss S, Saletta F, Gottschalk S, McCowage GB, Kramer B. Chimeric Antigen receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours. Cancer Gene Ther. 2021;28(3–4):321–34.32873870 10.1038/s41417-020-00221-4
215. Yi Z Prinzing BL Cao F Gottschalk S Krenciute G Optimizing EphA2-CAR T cells for the Adoptive Immunotherapy of Glioma Mol Ther Methods Clin Dev 2018 9 70 80 10.1016/j.omtm.2018.01.009 29552579
Yi Z, Prinzing BL, Cao F, Gottschalk S, Krenciute G. Optimizing EphA2-CAR T cells for the Adoptive Immunotherapy of Glioma. Mol Ther Methods Clin Dev. 2018;9:70–80.29552579 10.1016/j.omtm.2018.01.009
216. Lange S Sand LGL Bell M Patil SL Langfitt D Gottschalk S A chimeric GM-CSF/IL18 receptor to sustain CAR T-cell function Cancer Discov 2021 11 7 1661 71 10.1158/2159-8290.CD-20-0896 33563660
Lange S, Sand LGL, Bell M, Patil SL, Langfitt D, Gottschalk S. A chimeric GM-CSF/IL18 receptor to sustain CAR T-cell function. Cancer Discov. 2021;11(7):1661–71.33563660 10.1158/2159-8290.CD-20-0896
217. Muhammad N Wang R Li W Zhang Z Chang Y Hu Y A novel TanCAR targeting IL13Rα2 and EphA2 for enhanced glioblastoma therapy Mol Ther Oncolytics 2022 24 729 41 10.1016/j.omto.2022.02.012 35317513
Muhammad N, Wang R, Li W, Zhang Z, Chang Y, Hu Y, et al. A novel TanCAR targeting IL13Rα2 and EphA2 for enhanced glioblastoma therapy. Mol Ther Oncolytics. 2022;24:729–41.35317513 10.1016/j.omto.2022.02.012
218. Lin Q, Ba T, Ho J, Chen D, Cheng Y, Wang L et al. First-in-human trial of EphA2-Redirected CAR T-Cells in patients with recurrent glioblastoma: a preliminary Report of three cases at the starting dose. Front Oncol. 2021;11.
219. Fu C, Zhou L, Mi QS, Jiang A. DC-Based vaccines for Cancer Immunotherapy. Vaccines (Basel). 2020;8(4).
220. Patente TA Pinho MP Oliveira AA Evangelista GCM Bergami-Santos PC Barbuto JAM Human dendritic cells: their heterogeneity and clinical application potential in Cancer Immunotherapy Front Immunol 2018 9 3176 10.3389/fimmu.2018.03176 30719026
Patente TA, Pinho MP, Oliveira AA, Evangelista GCM, Bergami-Santos PC, Barbuto JAM. Human dendritic cells: their heterogeneity and clinical application potential in Cancer Immunotherapy. Front Immunol. 2018;9:3176.30719026 10.3389/fimmu.2018.03176
221. Huber A Dammeijer F Aerts J Vroman H Current state of dendritic cell-based immunotherapy: opportunities for in vitro Antigen Loading of different DC subsets? Front Immunol 2018 9 2804 10.3389/fimmu.2018.02804 30559743
Huber A, Dammeijer F, Aerts J, Vroman H. Current state of dendritic cell-based immunotherapy: opportunities for in vitro Antigen Loading of different DC subsets? Front Immunol. 2018;9:2804.30559743 10.3389/fimmu.2018.02804
222. Hatano M Kuwashima N Tatsumi T Dusak JE Nishimura F Reilly KM Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors J Transl Med 2004 2 1 40 10.1186/1479-5876-2-40 15563374
Hatano M, Kuwashima N, Tatsumi T, Dusak JE, Nishimura F, Reilly KM, et al. Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med. 2004;2(1):40.15563374 10.1186/1479-5876-2-40
223. Hatano M Eguchi J Tatsumi T Kuwashima N Dusak JE Kinch MS EphA2 as a glioma-associated antigen: a novel target for glioma vaccines Neoplasia 2005 7 8 717 22 10.1593/neo.05277 16207473
Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, et al. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia. 2005;7(8):717–22.16207473 10.1593/neo.05277
224. Chen H Yuan B Zheng Z Liu Z Wang S Liu Y A novel vaccine containing EphA2 epitope and LIGHT plasmid induces robust cellular immunity against glioma U251 cells Cell Immunol 2011 272 1 102 6 10.1016/j.cellimm.2011.08.011 22032907
Chen H, Yuan B, Zheng Z, Liu Z, Wang S, Liu Y. A novel vaccine containing EphA2 epitope and LIGHT plasmid induces robust cellular immunity against glioma U251 cells. Cell Immunol. 2011;272(1):102–6.22032907 10.1016/j.cellimm.2011.08.011
225. Yeung JT Hamilton RL Okada H Jakacki RI Pollack IF Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy J Neurooncol 2013 111 2 103 11 10.1007/s11060-012-0998-x 23179498
Yeung JT, Hamilton RL, Okada H, Jakacki RI, Pollack IF. Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy. J Neurooncol. 2013;111(2):103–11.23179498 10.1007/s11060-012-0998-x
226. Pollack IF Jakacki RI Butterfield LH Hamilton RL Panigrahy A Potter DM Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas J Clin Oncol 2014 32 19 2050 8 10.1200/JCO.2013.54.0526 24888813
Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Potter DM, et al. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol. 2014;32(19):2050–8.24888813 10.1200/JCO.2013.54.0526
227. Yamaguchi S Tatsumi T Takehara T Sakamori R Uemura A Mizushima T Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines Cancer 2007 110 7 1469 77 10.1002/cncr.22958 17685394
Yamaguchi S, Tatsumi T, Takehara T, Sakamori R, Uemura A, Mizushima T, et al. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer. 2007;110(7):1469–77.17685394 10.1002/cncr.22958
228. Yamaguchi S Tatsumi T Takehara T Sasakawa A Hikita H Kohga K Dendritic cell-based vaccines suppress metastatic liver tumor via activation of local innate and acquired immunity Cancer Immunol Immunother 2008 57 12 1861 9 10.1007/s00262-008-0514-5 18438665
Yamaguchi S, Tatsumi T, Takehara T, Sasakawa A, Hikita H, Kohga K, et al. Dendritic cell-based vaccines suppress metastatic liver tumor via activation of local innate and acquired immunity. Cancer Immunol Immunother. 2008;57(12):1861–9.18438665 10.1007/s00262-008-0514-5
229. Yamaguchi S Tatsumi T Takehara T Sasakawa A Yamamoto M Kohga K EphA2-derived peptide vaccine with amphiphilic poly(gamma-glutamic acid) nanoparticles elicits an anti-tumor effect against mouse liver tumor Cancer Immunol Immunother 2010 59 5 759 67 10.1007/s00262-009-0796-2 19943047
Yamaguchi S, Tatsumi T, Takehara T, Sasakawa A, Yamamoto M, Kohga K, et al. EphA2-derived peptide vaccine with amphiphilic poly(gamma-glutamic acid) nanoparticles elicits an anti-tumor effect against mouse liver tumor. Cancer Immunol Immunother. 2010;59(5):759–67.19943047 10.1007/s00262-009-0796-2
230. Storkus WJ, Maurer D, Lin Y, Ding F, Bose A, Lowe D et al. Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. J Immunother Cancer. 2021;9(11).
231. Upadhyaya P, Lahdenranta J, Hurov K, Battula S, Dods R, Haines E et al. Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist. J Immunother Cancer. 2021;9(1).
